{
  "studies": [
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03669003",
          "briefTitle": "Gelfoam to Prevent Pneumothorax After Lung Biopsy"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2018-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Miami"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pneumothorax Iatrogenic Postprocedural"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gelfoam slurry"
            },
            {
              "name": "CT-guided percutaneous lung biopsy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02727803",
          "briefTitle": "Personalized NK Cell Therapy in CBT"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2016-05-19"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-05-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
            "Acute Biphenotypic Leukemia",
            "Acute Lymphoblastic Leukemia",
            "Acute Lymphoblastic Leukemia in Remission",
            "Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
            "Acute Myeloid Leukemia With Variant MLL Translocations",
            "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",
            "Chemotherapy-Related Leukemia",
            "Chronic Myelomonocytic Leukemia",
            "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
            "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
            "ISS Stage II Plasma Cell Myeloma",
            "ISS Stage III Plasma Cell Myeloma",
            "Myelodysplastic Syndrome",
            "Myelodysplastic Syndrome With Excess Blasts",
            "Myelodysplastic Syndrome With Gene Mutation",
            "Myelodysplastic/Myeloproliferative Neoplasm",
            "Previously Treated Myelodysplastic Syndrome",
            "Recurrent Acute Myeloid Leukemia",
            "Recurrent Adult Acute Myeloid Leukemia",
            "Recurrent Hodgkin Lymphoma",
            "Recurrent Non-Hodgkin Lymphoma",
            "Refractory Acute Lymphoblastic Leukemia",
            "Refractory Adult Acute Lymphoblastic Leukemia",
            "Secondary Acute Myeloid Leukemia",
            "Therapy-Related Myelodysplastic Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Allogeneic Natural Killer Cell Line NK-92"
            },
            {
              "name": "Anti-Thymocyte Globulin"
            },
            {
              "name": "Busulfan"
            },
            {
              "name": "Clofarabine"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Fludarabine Phosphate"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Melphalan"
            },
            {
              "name": "Rituximab"
            },
            {
              "name": "Total-Body Irradiation"
            },
            {
              "name": "Umbilical Cord Blood Transplantation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05470803",
          "briefTitle": "An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "D'Or Institute for Research and Education"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID-19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 360,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "AstraZeneca/Fiocruz"
            },
            {
              "name": "Pfizer/Wyeth"
            },
            {
              "name": "Clover SCB-2019"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05403827",
          "briefTitle": "A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-07-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-08-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Kowa Research Institute, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dry Eye Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 644,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "K-161"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00219661",
          "briefTitle": "Effect of Drainage of Subglottic Secretions on Pneumonia Acquired Under Mechanical Ventilation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Poissy-Saint Germain Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "ICU's Patients Under Mechanical Ventilation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 440
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "drainage of subglottic secretions (HiLo Evac tube)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05547061",
          "briefTitle": "A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2021-04-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cellbion Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer",
            "mCRPC"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 91,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lu-177-DGUL"
            },
            {
              "name": "Ga-68-NGUL"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03012061",
          "briefTitle": "Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-01-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-05-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Asthma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 425,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "UMEC"
            },
            {
              "name": "Fluticasone Furoate"
            },
            {
              "name": "Albuterol/salbutamol"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01418742",
          "briefTitle": "SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Panitumumab, Doxycycline/Placebo"
            },
            {
              "name": "Panitumumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04082442",
          "briefTitle": "Evolocumab in Patients With Acute MI"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-09-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-10-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Johns Hopkins University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Coronary Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Evolocumab"
            },
            {
              "name": "Placebos"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05964686",
          "briefTitle": "The Efficacy of Laser in Root Canal Disinfection"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-01-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Future University in Egypt"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pulp and Periapical Tissue Disease",
            "Pulp Necroses",
            "Pulp; Granuloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Conventional group (NaOCl/EDTA)"
            },
            {
              "name": "Dual laser group (Er,Cr:YSGG/Diode):"
            },
            {
              "name": "Combined group (EDTA/Diode):"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05063786",
          "briefTitle": "Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2021-09-14"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Spanish Breast Cancer Research Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Trastuzumab"
            },
            {
              "name": "Alpelisib"
            },
            {
              "name": "Fulvestrant"
            },
            {
              "name": "Vinorelbine"
            },
            {
              "name": "Capecitabine"
            },
            {
              "name": "Eribulin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01789970",
          "briefTitle": "Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Teva Branded Pharmaceutical Products R&D, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Low Back Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 625,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hydrocodone ER"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03022370",
          "briefTitle": "Stepping Stones and Creating Futures Intervention Trial"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of KwaZulu"
          }
        },
        "conditionsModule": {
          "conditions": [
            "IPV",
            "Sexual Violence"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1351,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Stepping Stones and Creating Futures"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03359954",
          "briefTitle": "Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2017-11-16"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-10-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Estrogen Receptor Positive",
            "HER2/Neu Negative",
            "Invasive Breast Carcinoma",
            "Progesterone Receptor Positive"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Radiation Therapy"
            },
            {
              "name": "Therapeutic Conventional Surgery"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00167141",
          "briefTitle": "Contraception in Normal and Subnormal Men"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2005-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital Muenster"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Healthy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "injection of hormonal male contraceptive"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06247241",
          "briefTitle": "A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Versameb AG"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stress Urinary Incontinence"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "VMB-100"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01569841",
          "briefTitle": "A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novo Nordisk A/S"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes",
            "Diabetes Mellitus, Type 1"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "insulin degludec"
            },
            {
              "name": "insulin glargine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06596005",
          "briefTitle": "Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2024-09-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Second Affiliated Hospital, School of Medicine, Zhejiang University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "TJ0113"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01336205",
          "briefTitle": "Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AstraZeneca"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Opioid-Induced Constipation (OIC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 844,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NKTR-118"
            },
            {
              "name": "Usual care"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02769494",
          "briefTitle": "The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2016-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Xijing Hospital of Digestive Diseases"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Crohn's Disease",
            "Oral Ulcer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Mesalazine Sustained-Release Tablets"
            },
            {
              "name": "Riboflavin Sodium Phosphate Injection"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05966194",
          "briefTitle": "RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-04-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-07-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "EpicentRx, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Oral Mucositis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 216,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "RRx-001"
            },
            {
              "name": "Intensity Modulated Radiation Therapy (IMRT)"
            },
            {
              "name": "Cisplatin for injection 100 mg/m2"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00244166",
          "briefTitle": "Prednisolone in Active Ankylosing Spondylitis (AS)"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2002-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Charite University, Berlin, Germany"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ankylosing Spondylitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 75
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "prednisolone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00597766",
          "briefTitle": "Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "MetroHealth Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Shoulder Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lidocaine"
            },
            {
              "name": "Triamcinolone + Lidocaine"
            },
            {
              "name": "Triamcinolone + Lidocaine"
            },
            {
              "name": "Triamcinolone + Lidocaine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02225366",
          "briefTitle": "Intratumoral Injections of LL37 for Melanoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-07-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-11-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LL37"
            },
            {
              "name": "Photographs"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00498966",
          "briefTitle": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AEterna Zentaris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Perifosine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04561466",
          "briefTitle": "Trial of Befizal\u00ae 200 mg for the Treatment of Leber Hereditary Optic Neuropathy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-03-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H\u00f4pital Necker-Enfants Malades"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Safety Issues",
            "Efficacy, Self"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "B\u00e9fizal"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00038766",
          "briefTitle": "CNI-1493 for Treatment of Moderate to Severe Crohn's Disease"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2002-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2003-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ferring Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Crohn Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "semapimod"
            },
            {
              "name": "semapimod"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00102466",
          "briefTitle": "Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1007,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "vildagliptin"
            },
            {
              "name": "Gliclazide"
            },
            {
              "name": "Metformin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03542266",
          "briefTitle": "CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-06-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-03-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Weill Medical College of Cornell University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Previously Untreated Peripheral T-cell Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CC-486 Administration"
            },
            {
              "name": "CHOP Administration"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00831922",
          "briefTitle": "Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AB Science"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "masitinib (AB1010)"
            },
            {
              "name": "masitinib (AB1010)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04867551",
          "briefTitle": "A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-05-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-09-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Kissei Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "KDT-3594"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03182751",
          "briefTitle": "Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-04-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-05-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mayo Clinic"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hip Fractures",
            "Intertrochanteric Fractures"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 128,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tranexamic Acid (TXA)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01001351",
          "briefTitle": "A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Proteon Therapeutics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Kidney Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 89,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PRT-201"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01000129",
          "briefTitle": "Adaptive Planning in Bladder Cancer"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2009-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Royal Marsden NHS Foundation Trust"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Bladder Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)"
            },
            {
              "name": "Cone beam CT acquisition"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00018031",
          "briefTitle": "Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatitis C",
            "HIV Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Peginterferon alfa-2b"
            },
            {
              "name": "Ribavirin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03182231",
          "briefTitle": "GLP1-imaging Before and After Bariatric Surgery"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2016-10-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-07-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Radboud University Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2",
            "Bariatric Surgery Candidate"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "68Ga-NODAGA-exendin-4 PET/CT"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05809531",
          "briefTitle": "An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2023-05-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Apellis Pharmaceuticals, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "C3G",
            "IC-MPGN",
            "C3 Glomerulopathy",
            "C3 Glomerulonephritis",
            "Complement 3 Glomerulopathy",
            "Complement 3 Glomerulopathy (C3G)",
            "Complement 3 Glomerulonephritis",
            "Dense Deposit Disease",
            "DDD",
            "Membranoproliferative Glomerulonephritis",
            "Membranoproliferative Glomerulonephritis (MPGN)",
            "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pegcetacoplan"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07088731",
          "briefTitle": "Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cervical Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 180,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sintilimab"
            },
            {
              "name": "Concurrent chemo-radiotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00000102",
          "briefTitle": "Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets"
        },
        "statusModule": {
          "overallStatus": "COMPLETED"
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Center for Research Resources (NCRR)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Congenital Adrenal Hyperplasia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ]
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nifedipine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07064902",
          "briefTitle": "Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nasopharyngeal Carcinoma (NPC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ivonescimab\uff08AK112\uff0ca PD-1/VEGF bispecific antibody\uff09"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00003102",
          "briefTitle": "Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1998-11-17"
          },
          "primaryCompletionDateStruct": {
            "date": "2000-04-19"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ludwig Institute for Cancer Research"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00658645",
          "briefTitle": "Efficacy of Bifeprunox in Patients With Schizophrenia"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H. Lundbeck A/S"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Schizophrenia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 227,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bifeprunox"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Quetiapine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00766545",
          "briefTitle": "Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1992-04"
          },
          "primaryCompletionDateStruct": {
            "date": "1997-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Otsuka Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cerebral Infarction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1095,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "cilostazol"
            },
            {
              "name": "placebo of cilostazol"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05329545",
          "briefTitle": "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2022-06-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-09-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mersana Therapeutics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "High Grade Serous Ovarian Cancer",
            "Fallopian Tube Cancer",
            "Primary Peritoneal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Upifitimab rilsodotin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03260972",
          "briefTitle": "Intraabdominal Chloroprocaine During Cesarean Delivery for Pain Control"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2021-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Johns Hopkins University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cesarean Section Complications",
            "Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Chloroprocaine Hcl 2% Inj"
            },
            {
              "name": "Normal saline"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01073072",
          "briefTitle": "Study Comparing Tutomesh\u00ae Repair to Conventional Surgical Techniques in Potentially Contaminated Hernia Repair and Abdominal Wall Reconstruction"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centre Hospitalier R\u00e9gional Universitaire Montpellier"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Potentially Contaminated Hernia Repair",
            "Potentially Contaminated Abdominal Wall Reconstruction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 134,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Conventional technique"
            },
            {
              "name": "Technique Tutomesh\u00ae"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00991172",
          "briefTitle": "A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Regeneron Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sciatica"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 159,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "REGN475"
            },
            {
              "name": "REGN475"
            },
            {
              "name": "Placebo Injection"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01280695",
          "briefTitle": "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Metabolic Solutions Development Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 129,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "MSDC-0602 100 mg"
            },
            {
              "name": "MSDC-0602 250 mg"
            },
            {
              "name": "MSDC-0602 250 mg"
            },
            {
              "name": "Pioglitazone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02588339",
          "briefTitle": "Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-03-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-12-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H. Lee Moffitt Cancer Center and Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Graft Versus Host Disease",
            "GVHD"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Panobinostat"
            },
            {
              "name": "Sirolimus"
            },
            {
              "name": "Tacrolimus"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00363857",
          "briefTitle": "A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Restless Legs Syndrome (RLS)",
            "Restless Legs Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 360,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ropinirole"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00926575",
          "briefTitle": "Study of orBec\u00ae With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2009-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Soligenix"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Gastrointestinal Graft vs Host Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 140,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "oral beclomethasone 17,21-dipropionate"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02542657",
          "briefTitle": "Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2015-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Joseph Tuscano"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Myeloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Clarithromycin"
            },
            {
              "name": "Dexamethasone"
            },
            {
              "name": "Ixazomib Citrate"
            },
            {
              "name": "Pomalidomide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00226746",
          "briefTitle": "Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2003-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "New York Presbyterian Brooklyn Methodist Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Pancreatic Ductal"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Paclitaxel and gemcitabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01384188",
          "briefTitle": "A Study to Investigate the Effects of Food and Morning Versus Evening on Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ono Pharmaceutical Co. Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Healthy Post Menopausal Women"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ONO-5334"
            },
            {
              "name": "ONO-5334"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00610688",
          "briefTitle": "Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Children's Hospital Medical Center, Cincinnati"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Vitamin D Deficiency"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 192,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Prenatal Vitamin"
            },
            {
              "name": "Cholecalciferol (Vitamin D3)"
            },
            {
              "name": "Cholecalciferol (Vitamin D3)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06887088",
          "briefTitle": "Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-05-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Grupo Espa\u00f1ol Multidisciplinar de Melanoma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma BRAF V600E/K Mutated",
            "Melanoma and Brain Metastases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Encorafenib + Binimetinib"
            },
            {
              "name": "cemiplimab+fianlimab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03483103",
          "briefTitle": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-07-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-09-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Juno Therapeutics, a Subsidiary of Celgene"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymphoma, Non-Hodgkin",
            "Lymphoma, Nonhodgkin",
            "Lymphoma, B-Cell",
            "Lymphoma, Large B-Cell, Diffuse"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 74,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "lisocabtagene maraleucel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00569127",
          "briefTitle": "Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2007-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-01-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Neuroendocrine Tumor G1",
            "Gastric Neuroendocrine Tumor G1",
            "Neuroendocrine Neoplasm",
            "Neuroendocrine Tumor",
            "Neuroendocrine Tumor G2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 427,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bevacizumab"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Octreotide Acetate"
            },
            {
              "name": "Recombinant Interferon Alfa-2b"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02202161",
          "briefTitle": "A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-08-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-01-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GSK2330672"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Sitagliptin"
            },
            {
              "name": "Metformin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00799942",
          "briefTitle": "Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2009-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merz Pharmaceuticals GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nystagmus, Congenital",
            "Nystagmus, Acquired",
            "Multiple Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Neramexane mesylate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05292742",
          "briefTitle": "Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2021-07-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-10-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fujian Medical University Union Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer",
            "Adjuvant Therapy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 206,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pyrotinib+Trastuzumab+Capecitabine"
            },
            {
              "name": "Trastuzumab+Pertuzumab/Trastuzumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06575686",
          "briefTitle": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-03-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-07-16"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "City of Hope Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent Grade 1 Follicular Lymphoma",
            "Recurrent Grade 2 Follicular Lymphoma",
            "Recurrent Grade 3a Follicular Lymphoma",
            "Refractory Grade 1 Follicular Lymphoma",
            "Refractory Grade 2 Follicular Lymphoma",
            "Refractory Grade 3a Follicular Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Biospecimen Collection"
            },
            {
              "name": "Bone Marrow Biopsy"
            },
            {
              "name": "Computed Tomography"
            },
            {
              "name": "Epcoritamab"
            },
            {
              "name": "Positron Emission Tomography"
            },
            {
              "name": "Tazemetostat"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01209286",
          "briefTitle": "Study of the BiTE\u00ae Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Amgen Research (Munich) GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "B-ALL"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Blinatumomab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03344770",
          "briefTitle": "The Efficacy of Radial Extracorporeal Shockwave Therapy on Knee Osteoarthritis"
        },
        "statusModule": {
          "overallStatus": "SUSPENDED",
          "startDateStruct": {
            "date": "2017-10-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Marta Imamura"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Osteoarthritis, Knee"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 44,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Active rESWT"
            },
            {
              "name": "Sham rESWT"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06323473",
          "briefTitle": "Maitake for Integrative Cancer Care"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-10-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-11-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The Canadian College of Naturopathic Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Black Maitake Prothera"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06519773",
          "briefTitle": "Modified Periosteal Inhibition with Simultaneous Implant Placement in Aesthetic Zone"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tanta University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Immediate Dental Implant"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Modified periosteal inhibition"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05464173",
          "briefTitle": "Chidamide in Combination With Abemaciclib and Endocrinotherapy\uff08Doctor's Choice\uff09 in Breast Cancer Patients Previously Treated With Palbociclib"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-02-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Biyun Wang, MD"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 44,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Chidamide"
            },
            {
              "name": "Abemaciclib"
            },
            {
              "name": "endocrinotherapy\uff08doctor's choice\uff09"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06669169",
          "briefTitle": "Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-01-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tasly Pharmaceutical Group Co., Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Heart Failure"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 288,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Jia Shen Tablet Placebo"
            },
            {
              "name": "Low dose Jia Shen Tablet"
            },
            {
              "name": "High dose Jia Shen Tablet"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04415983",
          "briefTitle": "Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-06-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2030-10-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tanta University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Helicobacter Pylori Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nitazoxanide"
            },
            {
              "name": "Clarithromycin"
            },
            {
              "name": "Metronidazole"
            },
            {
              "name": "Proton pump inhibitor"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01061983",
          "briefTitle": "Electrical Stimulation of the Internal Capsule for Intractable Obsessive-compulsive Disorder (OCD)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Butler Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obsessive-Compulsive Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Medtronic Activa Deep Brain Stimulation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00301483",
          "briefTitle": "A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2004-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Biopure Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Wounds and Injuries"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 53,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hemoglobin-based oxygen carrier-201 (HBOC 201)"
            },
            {
              "name": "Standard of Care"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05437341",
          "briefTitle": "PSMA/CD70 Bi-specific CAR-T Cell Therapy"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-06-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shenzhen Geno-Immune Medical Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "bi-4SCAR PSMA/CD70 T cells"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00561054",
          "briefTitle": "Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2007-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Grupo Portugues de Estudo do Cancro do Pulmao"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 47,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CETUXIMAB"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06050954",
          "briefTitle": "A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2023-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fox Chase Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Urothelial Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pembrolizumab (200mg)"
            },
            {
              "name": "Pembrolizumab (400mg)"
            },
            {
              "name": "Monitoring"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00319254",
          "briefTitle": "Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Neoplasms",
            "Neoplasm Metastasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 75,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SKI-606 (Bosutinib)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04539483",
          "briefTitle": "Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2020-10-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-05-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Heidelberg ImmunoTherapeutics GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Herpes Labialis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 761,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "HDIT101 (blinded therapy)"
            },
            {
              "name": "Placebo (blinded therapy)"
            },
            {
              "name": "Photo documentation of orolabial herpes lesions"
            },
            {
              "name": "Completion of questionnaires (patient-reported outcomes)"
            },
            {
              "name": "28-day swabbing of orolabial region"
            },
            {
              "name": "Blood drawings"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00455754",
          "briefTitle": "Esomeprazole Treatment for Patients With Lymphocytic Gastritis"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2007-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Technische Universit\u00e4t Dresden"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymphocytic Gastritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 40
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Esomeprazole"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05914454",
          "briefTitle": "Efficacy and Safety of Anakinra in Acute Respiratory Distress Syndrome"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2023-05-19"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-06-19"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Azienda Sanitaria-Universitaria Integrata di Udine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Respiratory Distress Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Anakinra 100Mg/0.67Ml Inj Syringe"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03973554",
          "briefTitle": "Caries Prevention Potential of Pearl Powder Versus CPP-ACP on Enamel White Spot Lesions"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-10-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-10-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ruba Alaa El Din Adel El Damarisy"
          }
        },
        "conditionsModule": {
          "conditions": [
            "White Spot Lesion of Tooth"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "pearl powder"
            },
            {
              "name": "CPP-ACP"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00785954",
          "briefTitle": "Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "KAI Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Myocardial Infarction",
            "Cardiovascular Diseases",
            "Pathologic Processes"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1180,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "KAI-9803"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02520154",
          "briefTitle": "Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-07-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-05-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stage III Fallopian Tube Cancer AJCC v7",
            "Stage III Ovarian Cancer AJCC v6 and v7",
            "Stage III Primary Peritoneal Cancer AJCC v7",
            "Stage IIIA Fallopian Tube Cancer AJCC v7",
            "Stage IIIA Ovarian Cancer AJCC v6 and v7",
            "Stage IIIA Primary Peritoneal Cancer AJCC v7",
            "Stage IIIB Fallopian Tube Cancer AJCC v7",
            "Stage IIIB Ovarian Cancer AJCC v6 and v7",
            "Stage IIIB Primary Peritoneal Cancer AJCC v7",
            "Stage IIIC Fallopian Tube Cancer AJCC v7",
            "Stage IIIC Ovarian Cancer AJCC v6 and v7",
            "Stage IIIC Primary Peritoneal Cancer AJCC v7",
            "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
            "Stage IV Ovarian Cancer AJCC v6 and v7",
            "Stage IV Primary Peritoneal Cancer AJCC v7"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Carboplatin"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Pembrolizumab"
            },
            {
              "name": "Pharmacological Study"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00668005",
          "briefTitle": "Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bayer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Erectile Dysfunction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 388,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Levitra (Vardenafil, BAY38-9456)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04635605",
          "briefTitle": "Methylene Blue Treatment of COVID-19"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-11-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-08-13"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fondazione Epatocentro Ticino"
          }
        },
        "conditionsModule": {
          "conditions": [
            "SARS-CoV2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Methylene Blue"
            },
            {
              "name": "Control Test"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05835505",
          "briefTitle": "Detoxification of the Liver In PSC (Dolphin)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-12-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Brigham and Women's Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Primary Sclerosing Cholangitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 28,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BRS201"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05678205",
          "briefTitle": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2023-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Artiva Biotherapeutics, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer",
            "Gastric Cancer",
            "Gastroesophageal Junction Adenocarcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "AB-201"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Fludarabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00755794",
          "briefTitle": "The Singulair\u00ae add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Organon and Co"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Asthma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 800,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "montelukast sodium"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07145294",
          "briefTitle": "Induced Pluripotent Stem Cells-derived Small Extracellular Vesicles May Promote Neurological Function and Improve Cognitive Impairment in Acute Ischemic Stroke Patients"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-03-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-07-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hongmei Wang"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cognitive Impairment"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "iEV"
            },
            {
              "name": "Basic treatments"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05901194",
          "briefTitle": "Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2024-07-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assistance Publique - H\u00f4pitaux de Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma Non-resectable"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lenvatinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02172456",
          "briefTitle": "Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2002-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2002-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Boehringer Ingelheim"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pulmonary Disease, Chronic Obstructive"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "99mTc-radiolabelled tiotropium"
            },
            {
              "name": "non-radiolabelled tiotropium"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05626166",
          "briefTitle": "the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-12-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tanta University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ulcerative Colitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "Diosmin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01715922",
          "briefTitle": "Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2012-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ANRS, Emerging Infectious Diseases"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cryptococcal Meningitis",
            "HIV"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fluconazole"
            },
            {
              "name": "Flucytosine"
            },
            {
              "name": "lumbar punctures"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02433522",
          "briefTitle": "Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-03-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-08-16"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assistance Publique - H\u00f4pitaux de Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "ANCA-associated Vasculitides"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 97,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "rituximab"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05907122",
          "briefTitle": "A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO\u00ae (Nivolumab) in Subjects With Resected Melanoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2023-07-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Amgen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 256,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ABP 206"
            },
            {
              "name": "FDA-licensed Nivolumab"
            },
            {
              "name": "EU-authorized Nivolumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04002622",
          "briefTitle": "Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2019-08-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-01-21"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "TQB2450"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05963022",
          "briefTitle": "A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-08-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-10-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Type 2 Diabetes"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 168,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tirzepatide"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02092922",
          "briefTitle": "A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Multiple Myeloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 154,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Filanesib, KSP (Eg5) inhibitor; intravenous"
            },
            {
              "name": "Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06120751",
          "briefTitle": "A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2024-03-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-04-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "CanSino Biologics Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Tetanus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1000,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "TTVA"
            },
            {
              "name": "TT"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01274351",
          "briefTitle": "Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-01-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-08-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Myelogenous Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 112,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nilotinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02114229",
          "briefTitle": "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2014-05-14"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "St. Jude Children's Research Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malignant Rhabdoid Tumor",
            "Atypical Teratoid Rhabdoid Tumor"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 125,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "alisertib"
            },
            {
              "name": "methotrexate"
            },
            {
              "name": "cisplatin"
            },
            {
              "name": "carboplatin"
            },
            {
              "name": "cyclophosphamide"
            },
            {
              "name": "etoposide"
            },
            {
              "name": "topotecan"
            },
            {
              "name": "vincristine"
            },
            {
              "name": "Surgical resection"
            },
            {
              "name": "Radiation therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03142529",
          "briefTitle": "Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2017-05-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-08-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pang Peng"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Kidney Failure",
            "End-Stage Kidney Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "colon lotion"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00001031",
          "briefTitle": "A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults"
        },
        "statusModule": {
          "overallStatus": "COMPLETED"
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 296,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "rgp120/HIV-1MN"
            },
            {
              "name": "rgp120/HIV-1 SF-2"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05257031",
          "briefTitle": "Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-02-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-09-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fresenius Kabi"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nutrition Therapy",
            "Critical Illness"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SmofKabiven extra Nitrogen"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00775931",
          "briefTitle": "Allogeneic Transplantation For Severe Osteopetrosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Masonic Cancer Center, University of Minnesota"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Severe Osteopetrosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "umbilical cord blood transplantation"
            },
            {
              "name": "Campath-1H"
            },
            {
              "name": "Total Lymphoid Irradiation"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Busulfan"
            },
            {
              "name": "Fludarabine monophosphate"
            },
            {
              "name": "marrow graft transplantation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04767802",
          "briefTitle": "PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-02-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-03-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Protagonist Therapeutics, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Polycythemia Vera"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PTG-300"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00077402",
          "briefTitle": "Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cancer Therapeutics Research Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "fenretinide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04476953",
          "briefTitle": "COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-08-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mayo Clinic"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Covid19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "Fisetin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06437353",
          "briefTitle": "Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-05-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Anhui Provincial Cancer Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ovarian Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03919253",
          "briefTitle": "Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-04-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-04-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hebei Medical University Fourth Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HER2-positive Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "pyrotinib maleate tablets+nab-paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02525653",
          "briefTitle": "Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Cancer",
            "Untreated Stage IV or Recurrent Squamous Cell Lung Cancers"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "albumin-bound paclitaxel"
            },
            {
              "name": "gemcitabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01538472",
          "briefTitle": "Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Y Zevalin"
            },
            {
              "name": "In Zevalin"
            },
            {
              "name": "Rituxan"
            },
            {
              "name": "BCNU"
            },
            {
              "name": "VP -16"
            },
            {
              "name": "Ara-C"
            },
            {
              "name": "Melphalan"
            },
            {
              "name": "Stem Cell Infusion"
            },
            {
              "name": "G-CSF"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05214495",
          "briefTitle": "Omega-3 Hydrogel and Prevention of Oral Mucositis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-02-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Basma Morsy"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mucositis Oral"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "topical oral Omega-3 hydrogel"
            },
            {
              "name": "conventional preventive treatment"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05139095",
          "briefTitle": "Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-01-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Peking Union Medical College Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gestational Trophoblastic Neoplasia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Camrelizumab plus apatinib CohortA"
            },
            {
              "name": "Camrelizumab plus apatinib Cohort B"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04061395",
          "briefTitle": "Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-10-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-12-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Medical Center Groningen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hidradenitis Suppurativa"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Guselkumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04559139",
          "briefTitle": "Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2021-02-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2029-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ECOG-ACRIN Cancer Research Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stage II Gallbladder Cancer AJCC v8",
            "Stage IIA Gallbladder Cancer AJCC v8",
            "Stage IIB Gallbladder Cancer AJCC v8",
            "Stage III Gallbladder Cancer AJCC v8",
            "Stage IIIA Gallbladder Cancer AJCC v8",
            "Stage IIIB Gallbladder Cancer AJCC v8"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 186,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cisplatin"
            },
            {
              "name": "Gemcitabine Hydrochloride"
            },
            {
              "name": "Lymphadenectomy"
            },
            {
              "name": "Partial Hepatectomy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00052039",
          "briefTitle": "A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2002-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "InterMune"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Disease",
            "Pulmonary Fibrosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "interferon-gamma 1b"
            },
            {
              "name": "azathioprine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01468077",
          "briefTitle": "A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hoffmann-La Roche"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tocilizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00490724",
          "briefTitle": "An Exploratory Study of Nesiritide in Participants With Acute Heart Failure"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Janssen Pharmaceutical K.K."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Heart Failure, Congestive"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nesiritide (1+0.01)"
            },
            {
              "name": "Nesiritide (2+0.005)"
            },
            {
              "name": "Nesritide (2+0.01)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00617123",
          "briefTitle": "Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-10-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merck Sharp & Dohme LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Atherosclerosis",
            "Ischemia",
            "Myocardial Infarction",
            "Cerebrovascular Accident"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 258,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vorapaxar 2.5 mg"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00215423",
          "briefTitle": "Study in Patients With COPD"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "primaryCompletionDateStruct": {
            "date": "2003-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Dey"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COPD",
            "Chronic Obstructive Pulmonary Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 49
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Formoterol Fumarate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00137423",
          "briefTitle": "Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Renal Cell Metastasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SU011248 (sunitinib)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00489359",
          "briefTitle": "Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ovarian Cancer",
            "Primary Peritoneal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 86,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pemetrexed - Phase 1"
            },
            {
              "name": "Carboplatin - Phase 1"
            },
            {
              "name": "Pemetrexed - Phase 2"
            },
            {
              "name": "Carboplatin - Phase 2"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00017680",
          "briefTitle": "Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1999-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Herbert Irving Comprehensive Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Amyloidosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Melphalan"
            },
            {
              "name": "Autologous Stem Cell Transplantation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04642079",
          "briefTitle": "Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-12-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-04-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pneumococcal Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 839,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "20vPnC"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04361162",
          "briefTitle": "Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-05-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Massachusetts General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Cancer",
            "Metastatic Pancreatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nivolumab"
            },
            {
              "name": "Ipilimumab"
            },
            {
              "name": "Radiation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02004262",
          "briefTitle": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-02-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Aduro Biotech, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 303,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GVAX Pancreas Vaccine"
            },
            {
              "name": "CRS-207"
            },
            {
              "name": "Chemotherapy"
            },
            {
              "name": "cyclophosphamide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06551246",
          "briefTitle": "Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children with Daytime Urinary Incontinence (BeDry)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-06-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Aarhus"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Urinary Incontinence in Children"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 236,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Solifenacin"
            },
            {
              "name": "Mirabegron"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00743288",
          "briefTitle": "Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Oncotherapeutics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Myeloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Melphalan"
            },
            {
              "name": "Panobinostat"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00104988",
          "briefTitle": "S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "SWOG Cancer Research Network"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma (Skin)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "temozolomide"
            },
            {
              "name": "thalidomide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00519688",
          "briefTitle": "UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Taiwan University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 44,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Thalidomide"
            },
            {
              "name": "Tegafur/Uracil"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00632203",
          "briefTitle": "Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-03-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merck Sharp & Dohme LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung",
            "Adenocarcinoma",
            "Carcinoma, Large Cell",
            "Carcinoma, Squamous Cell"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 53,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Temozolomide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02866227",
          "briefTitle": "TOL-463 Phase 2 Study for Vaginitis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-07-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-06-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Toltec Pharmaceuticals, LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Bacterial Vaginosis",
            "Vulvovaginal Candidiasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 106,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "TOL-463"
            },
            {
              "name": "TOL-463"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06911827",
          "briefTitle": "A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Qilu Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Solid Tumor"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "QLP2117"
            },
            {
              "name": "QL2107"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00739661",
          "briefTitle": "A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Genentech, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ovarian Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 104,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vismodegib 150 mg"
            },
            {
              "name": "Placebo to vismodegib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01022242",
          "briefTitle": "Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pergamum AB"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Surgical Adhesions"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 138,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PXL01"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00485342",
          "briefTitle": "RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2006-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hospices Civils de Lyon"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Hepatitis C"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 236,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Peg-interferon alpha 2a and ribavin"
            },
            {
              "name": "ribavirin with adaptation dose"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00790842",
          "briefTitle": "Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2009-01-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "PrECOG, LLC."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Myeloma",
            "Plasma Cell Neoplasm"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lenalidomide"
            },
            {
              "name": "Dexamethasone"
            },
            {
              "name": "Anticoagulants"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05827042",
          "briefTitle": "Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-05-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The First Affiliated Hospital of University of Science and Technology of China"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Basilar Artery Occlusion",
            "Acute Cerebrovascular Accident",
            "Stroke Due to Basilar Artery Occlusion"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 338,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Intravenous thrombolysis"
            },
            {
              "name": "Endovascular thrombectomy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04636242",
          "briefTitle": "Photodynamic Therapy for Cutibacterium Acnes (C. Acnes) Decolonization of the Shoulder Dermis"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-08-22"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Rothman Institute Orthopaedics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "C. Acnes",
            "Phototherapy",
            "Postoperative Infection",
            "Arthroscopic Rotator Cuff Repair",
            "Shoulder Surgery"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Skin Biopsy"
            },
            {
              "name": "5 Aminolevulinic Acid + Phototherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00447642",
          "briefTitle": "Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2007-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lux Biosciences, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Corneal Transplantation",
            "Corneal Graft Rejection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 122,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LX201"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05302986",
          "briefTitle": "Effect on Post-operative Pain of Tranexamic Acid Injection During Shoulder Surgery"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-02-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Elsan"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Shoulder Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 220,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tranexamic acid injection"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04578470",
          "briefTitle": "Benign Paroxysmal Positional Vertigo (BPPV) in Older Patients"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-11-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-11-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Changi General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Benign Paroxysmal Positional Vertigo"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vitamin D"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00481169",
          "briefTitle": "Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Wyeth is now a wholly owned subsidiary of Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Osteoporosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1742,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bazedoxifene Acetate (TSE-424)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04452669",
          "briefTitle": "VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-09-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-06-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Aerogen Pharma Limited"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID-19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00604383",
          "briefTitle": "Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chromaderm, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetic Retinopathy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 685,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ruboxistaurin"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00688883",
          "briefTitle": "Fludara (Oral) Phase II Study for Indolent Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Genzyme, a Sanofi Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fludarabine Phosphate (Fludara)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03578783",
          "briefTitle": "PSD502 in Subjects With Premature Ejaculation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-12-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-05-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Plethora Solutions Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Premature Ejaculation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 121,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "PSD502"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00036283",
          "briefTitle": "Chemoprevention of Oral Premalignant Lesions"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2000-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Precancerous Conditions"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Celecoxib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03807141",
          "briefTitle": "Evaluation of the Modified Atkins Diet in Children With Epileptic Spasms"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-01-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-01-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lady Hardinge Medical College"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Epileptic Spasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Modified Atkins diet"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06915441",
          "briefTitle": "Lipid Infusions to Optimize Nutrition Trial"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-07-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The University of Texas Health Science Center, Houston"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Bronchopulmonary Dysplasia",
            "Neurodevelopmental Impairment"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 230,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SOLE"
            },
            {
              "name": "MOLE"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02273141",
          "briefTitle": "Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Norgine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Cancer",
            "Colorectal Carcinoma",
            "Colon Cleansing"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 515,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NER1006, Day Before-Only Dosing"
            },
            {
              "name": "SP+MS, Day Before-Only Dosing"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02859454",
          "briefTitle": "Avelumab for People With Recurrent Respiratory Papillomatosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-08-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent Respiratory Papillomatosis",
            "Juvenile Laryngeal Papilloma",
            "Laryngeal Papilloma, Recurrent",
            "Respiratory Papillomatosis",
            "Human Papilloma Virus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Avelumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06748105",
          "briefTitle": "Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2024-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lauro Fabi\u00e1n Amador Medina"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dapagliflozin (Forxiga)",
            "Hyperglycaemia",
            "Glucocorticoid"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dapagliflozin (DAPA)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03882905",
          "briefTitle": "A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-01-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2001-07-27"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Organon and Co"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Primary Hypercholesterolemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 769,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ezetimibe"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Simivastatin"
            },
            {
              "name": "Statin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07082205",
          "briefTitle": "Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-05-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Liverpool School of Tropical Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malaria",
            "Severe Malaria",
            "Severe Anaemia",
            "Post Discharge"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 398,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Antimalarial monoclonal antibodies"
            },
            {
              "name": "Dihydroartemisinin - Piperaquine (DP)"
            },
            {
              "name": "Placebo mMAB"
            },
            {
              "name": "Placebo PDMC"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03833466",
          "briefTitle": "Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-02-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-03-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Peking University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Esophageal Squamous Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "metformin and chemotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03806556",
          "briefTitle": "A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2019-04-22"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-08-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Meghan McCormick"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pediatric Cancer",
            "Thrombocytopenia",
            "Hemostatic Disorder",
            "Coagulation Defect; Acquired"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tranexamic Acid"
            },
            {
              "name": "Normal saline"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01937156",
          "briefTitle": "A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Solasia Pharma K.K."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chemotherapy-induced Nausea and Vomiting"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 313,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SP-01 (Granisetron Transdermal Delivery System)"
            },
            {
              "name": "Granisetron Hydrochloride Tablet"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06390956",
          "briefTitle": "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-01-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2031-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Utah"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Marginal Zone Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 23,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pirtobrutinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01924156",
          "briefTitle": "DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2013-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Affiliated Hospital to Academy of Military Medical Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Renal Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "adenovirus-transfected DC + CIK"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01210222",
          "briefTitle": "Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-06-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07-16"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gynecologic Oncology Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Endometrial Adenocarcinoma",
            "Endometrial Adenosquamous Carcinoma",
            "Endometrial Clear Cell Adenocarcinoma",
            "Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation",
            "Endometrial Serous Adenocarcinoma",
            "Endometrioid Stromal Sarcoma",
            "Recurrent Uterine Corpus Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Trebananib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00443651",
          "briefTitle": "A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Genentech, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 578,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rituximab"
            },
            {
              "name": "Anti-inflammatory drugs"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00666029",
          "briefTitle": "Implications for Treatment of the Metabolic Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital Southampton NHS Foundation Trust"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metabolic Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "atorvastatin"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01334931",
          "briefTitle": "Use of Large Field of View During Image Acquisition for Coronary Angiography"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Instituto de Cardiologia do Rio Grande do Sul"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Exposure to Ionizing Radiation",
            "Occupational Exposure to Radiation",
            "Radiation Injury"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Large field of view arm"
            },
            {
              "name": "Medium field of view"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06979531",
          "briefTitle": "Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-06-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Immunovant Sciences GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Primary Sj\u00f6gren's Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 180,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "IMVT-1402"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01830153",
          "briefTitle": "RAD001 in Advanced Sarcoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Asan Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Soft Tissue Sarcomas",
            "Bone Sarcomas"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "RAD001"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02246153",
          "briefTitle": "Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2014-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Nanfang Hospital, Southern Medical University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Complications"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 202,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Laparoscopic gastrectomy"
            },
            {
              "name": "Open gastrectomy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00000572",
          "briefTitle": "Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1987-06"
          },
          "primaryCompletionDateStruct": {
            "date": "1991-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Intermountain Health Care, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Respiratory Distress Syndrome",
            "Lung Diseases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "positive-pressure ventilation"
            },
            {
              "name": "extracorporeal membrane oxygenation (CO2 removal)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00321672",
          "briefTitle": "Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "NeurogesX"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pain",
            "HIV Infections",
            "Peripheral Nervous System Diseases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 494,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NGX-4010, 8% capsaicin patch"
            },
            {
              "name": "0.04% capsaicin patch"
            },
            {
              "name": "NGX-4010, 8% capsaicin patch"
            },
            {
              "name": "0.04% capsaicin patch"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02055872",
          "briefTitle": "Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hamilton Health Sciences Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Edema",
            "Hypoproteinemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Intravenous albumin"
            },
            {
              "name": "Normal saline"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01906372",
          "briefTitle": "Acthar in Treatment of Refractory Dermatomyositis and Polymyositis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Rohit Aggarwal, MD"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dermatomyositis",
            "Polymyositis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Adrenocorticotropic Hormone Gel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02514772",
          "briefTitle": "GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan\u00ae or MabThera\u00ae"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sandoz"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GP2013 - A Proposed biosimilar rituximab"
            },
            {
              "name": "Originator rituximab - Rituxan \u00ae or MabThera \u00ae"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02642939",
          "briefTitle": "Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2015-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-10-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Check, Jerome H., M.D., Ph.D."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-Small Cell Lung Cancer (NSCLC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Mifepristone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00015977",
          "briefTitle": "Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2003-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Chicago"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PSA prostate cancer vaccine"
            },
            {
              "name": "recombinant interleukin-12"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03272477",
          "briefTitle": "Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-10-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-07-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Palleos Healthcare GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Neoplasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 257,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Perjeta Injectable Product"
            },
            {
              "name": "Herceptin"
            },
            {
              "name": "Tamoxifen"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Epirubicin"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Anastrozole"
            },
            {
              "name": "Letrozole"
            },
            {
              "name": "Exemestane"
            },
            {
              "name": "Leuprorelin acetate"
            },
            {
              "name": "Goserelin"
            },
            {
              "name": "Anastrozole"
            },
            {
              "name": "Letrozole"
            },
            {
              "name": "Exemestane"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Tamoxifen"
            },
            {
              "name": "Leuporelin acetate"
            },
            {
              "name": "Goserelin"
            },
            {
              "name": "Biopsy"
            },
            {
              "name": "Surgery"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02144077",
          "briefTitle": "Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-01-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-11-17"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Biofrontera Bioscience GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Basal Cell Carcinoma (BCC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 281,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BF-200 ALA"
            },
            {
              "name": "methyl-aminolevulinate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01857869",
          "briefTitle": "Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-na\u00efve Adults"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-05-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-03-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malaria"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GSK257049 Dosage 1"
            },
            {
              "name": "GSK257049 Dosage 2"
            },
            {
              "name": "Sporozoite-infected mosquitoes challenge"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00636441",
          "briefTitle": "Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Duke University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Early-Stage Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02577341",
          "briefTitle": "Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-small-cell Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 122,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nimotuzumab"
            },
            {
              "name": "docetaxel and cisplatin"
            },
            {
              "name": "daily RT to the chest"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06966154",
          "briefTitle": "A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-05-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-05-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fudan University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Natural Killer/T-cell Lymphoma",
            "Relapsed or Refractory Lymphoma Including ENKL"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 68,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "tislezumab"
            },
            {
              "name": "golidocitinib"
            },
            {
              "name": "Selinexor"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00113854",
          "briefTitle": "Mannitol as Adjunct Therapy for Childhood Cerebral Malaria"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2004-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Makerere University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cerebral Malaria"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 156
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Mannitol"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02326805",
          "briefTitle": "PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-06-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-11-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stage I Prostate Adenocarcinoma AJCC v7",
            "Stage II Prostate Adenocarcinoma AJCC v7"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 154,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Placebo Administration"
            },
            {
              "name": "Rilimogene Galvacirepvec"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04594005",
          "briefTitle": "CDK4/6 Tumor, Abemaciclib, Paclitaxel"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-02-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-07-16"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Yonsei University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Tumors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "abemaciclib+paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07006805",
          "briefTitle": "RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cabaletta Bio"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Relapsing Multiple Sclerosis (RMS)",
            "Progressive Multiple Sclerosis (PMS)",
            "Multiple Sclerosis - Relapsing Remitting",
            "Multiple Sclerosis",
            "Multiple Sclerosis (Relapsing Remitting)",
            "Multiple Sclerosis (MS) - Relapsing-remitting",
            "Progressive Multiple Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CABA-201"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01611194",
          "briefTitle": "mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-09-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "U.S. Army Medical Research and Development Command"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Traumatic Brain Injury With Brief Loss of Consciousness",
            "Post-Concussion Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 71,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hyperbaric oxygen (HBO2) at 1.5 atms"
            },
            {
              "name": "Sham control 1.2 atms"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04614766",
          "briefTitle": "A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2022-09-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-04-23"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "David Bushnell"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gastro-enteropancreatic Neuroendocrine Tumor",
            "Neuroendocrine Tumors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lutathera"
            },
            {
              "name": "Azedra"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06036966",
          "briefTitle": "The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2023-09-16"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-07-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Thrombocytopenia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 34,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hetrombopag"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00248066",
          "briefTitle": "Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sarepta Therapeutics, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Coronary Artery Disease",
            "Coronary Restenosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "RESTEN-MP"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00675922",
          "briefTitle": "Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "1995-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The University of Texas Medical Branch, Galveston"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Burn"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 98,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sulfamylon 5% and Silver Nitrate Soaks"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06782022",
          "briefTitle": "DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-02-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-08-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Jan Gerard Maring"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gastrointestinal Cancers"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "5-Fluoro-Uracil"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00436722",
          "briefTitle": "Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2006-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hospital Clinic of Barcelona"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Liver Diseases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ATG (Fresenius Biotech)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03725722",
          "briefTitle": "Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-12-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-05-19"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "LEO Pharma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Atopic Dermatitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 251,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Delgocitinib cream"
            },
            {
              "name": "Delgocitinib cream vehicle"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04147351",
          "briefTitle": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors."
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-04-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Taiwan University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "NSCLC Stage IIIB~IV"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 22,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Atezolizumab Injection; bevacizumab Injection"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00763451",
          "briefTitle": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sanofi"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 484,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lixisenatide (AVE0010)"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Pen auto-injector"
            },
            {
              "name": "Metformin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01555229",
          "briefTitle": "Effect of Intermittent Versus Continuous Subglottic Secretion Drainage on Tracheal Mucosa Damages"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Rennes University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mechanical Ventilation Complication"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Intermittent subglottic secretion drainage"
            },
            {
              "name": "Continuous subglottic secretion drainage"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02135029",
          "briefTitle": "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hyperlipidemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 184,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bococizumab (PF-04950615;RN316)"
            },
            {
              "name": "Atorvastatin"
            },
            {
              "name": "Placebo for Bococizumab (PF-04950615;RN316)"
            },
            {
              "name": "Placebo for atorvastatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00115531",
          "briefTitle": "Eldery High Dose TIV 2005"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Influenza"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 414,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Trivalent inactivated influenza vaccine"
            },
            {
              "name": "Trivalent inactivated influenza vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03804931",
          "briefTitle": "Fecal Microbiota Transplantation for Ulcerative Colitis"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2019-01-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Guangzhou First People's Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ulcerative Colitis",
            "Fecal Microbiota Transplantation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fecal microbiota transplantation"
            },
            {
              "name": "Infusion of Saline"
            },
            {
              "name": "5-Aminosalicylic acid(5-ASA) and/or Prednisone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00266331",
          "briefTitle": "RayGel-An Alternative for Skin Care During External Beam Radiation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Nathalie Johnson"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Reduced glutathione"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01465802",
          "briefTitle": "Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-12-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-05-18"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non Small Cell Lung Cancer (NSCLC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 236,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dacomitinib"
            },
            {
              "name": "Dacomitinib"
            },
            {
              "name": "Doxycycline"
            },
            {
              "name": "Probiotic"
            },
            {
              "name": "Alclometasone cream"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01987453",
          "briefTitle": "Ledipasvir/Sofosbuvir Fixed-Dose Combination \u00b1 Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gilead Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HCV Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LDV/SOF"
            },
            {
              "name": "RBV"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00517153",
          "briefTitle": "Miglustat in Niemann-Pick Type C Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2002-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Actelion"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Niemann-Pick Type C Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "miglustat"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02497053",
          "briefTitle": "Four Versus Six Cycles of Pemetrexed/Platinum for MPM"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2015-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ain Shams University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malignant Pleural Mesothelioma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "pemetrexed/platinum chemotherapy"
            },
            {
              "name": "Pemetrexed/platinum chemotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00147953",
          "briefTitle": "Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Cologne"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-Hodgkin's Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rituximab"
            },
            {
              "name": "Total nodal irradiation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00966953",
          "briefTitle": "Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Colgate Palmolive"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gingival Diseases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fluoride"
            },
            {
              "name": "Triclosan/Fluoride toothpaste"
            },
            {
              "name": "Fluoride"
            },
            {
              "name": "Fluoride"
            },
            {
              "name": "antibacterial plant extract"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02638337",
          "briefTitle": "Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-01-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-06-23"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shionogi"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Vaginal Dryness"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 631,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ospemifene"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01883245",
          "briefTitle": "Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Chronic Orofacial Pain"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2013-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital of Ferrara"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Orofacial Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "real tDCS"
            },
            {
              "name": "sham tDCS"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02866045",
          "briefTitle": "EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2016-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Unity Health Toronto"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Disorder of Upper Gastrointestinal Tract",
            "Gastrointestinal Stromal Tumors",
            "Gastrointestinal Neoplasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 104,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "EUS-guided fine needle biopsy"
            },
            {
              "name": "Single incision needle knife biopsy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01824095",
          "briefTitle": "Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2013-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Logan University, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ankle Sprains"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 73,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dietary supplement"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00244595",
          "briefTitle": "Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AstraZeneca"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hypertension"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 235
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "candsartan cilexetil"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05764239",
          "briefTitle": "Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2023-07-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-03-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Synlogic"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Phenylketonuria"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SYNB1934v1"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01293539",
          "briefTitle": "Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Retinoblastoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Melphalan hydrochloride"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00843739",
          "briefTitle": "Expiratory Muscle Training in Patients With Parkinson's Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Florida"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "EMST - Active Treatment"
            },
            {
              "name": "sham EMST"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01897077",
          "briefTitle": "The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2012-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-02-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Johns Hopkins University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Peanut Allergy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Peanut Dissolving Film"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03334539",
          "briefTitle": "A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-11-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-04-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "HanAll BioPharma Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dry Eye"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "HL036 ophthalmic solution"
            },
            {
              "name": "Placebo vehicle solution"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05438875",
          "briefTitle": "The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-10-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-11-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Peking University People's Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Purpura, Thrombocytopenic, Idiopathic"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 96,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "all-trans retinoic acid"
            },
            {
              "name": "Eltrombopag"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05019677",
          "briefTitle": "GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2021-09-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fudan University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Intrahepatic Cholangiocarcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GP+PD-1+Tight"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01954277",
          "briefTitle": "Immune-Pineal Axis Function in Chronic Tension-Type Headache"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hospital de Clinicas de Porto Alegre"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Tension-Type Headache"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Electroacupuncture"
            },
            {
              "name": "Placebo Sham"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01884675",
          "briefTitle": "Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension."
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2013-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hypertension"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ambrisentan 5 mg"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07013201",
          "briefTitle": "A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-09-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "LEO Pharma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Palmoplantar Pustulosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 135,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Delgocitinib cream"
            },
            {
              "name": "Vehicle cream"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04671901",
          "briefTitle": "A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2020-12-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-03-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Solid Tumor",
            "Solid Tumor, Childhood",
            "Solid Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Romiplostim"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07047001",
          "briefTitle": "Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2025-04-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2029-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Dong Wen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Renal Cell Carcinoma (RCC)",
            "Adjuvant"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vorolanib Tablets"
            },
            {
              "name": "Vorolanib + Toripalimab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04610801",
          "briefTitle": "Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2021-12-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-06-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Larkin Community Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Covid19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nasal Spray"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00004001",
          "briefTitle": "S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1999-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "SWOG Cancer Research Network"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 770,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "docetaxel"
            },
            {
              "name": "estramustine"
            },
            {
              "name": "mitoxantrone"
            },
            {
              "name": "prednisone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01030601",
          "briefTitle": "Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Health Network, Toronto"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes",
            "Macular Edema",
            "Pseudophakia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dexamethasone sodium phosphate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06382012",
          "briefTitle": "Antiemetic Fosaprepitant To Remedy Nausea and Vomiting"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-11-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Montefiore Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nausea and Vomiting",
            "Nausea",
            "Vomiting"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fosaprepitant 150 mg"
            },
            {
              "name": "Ondansetron 4 mg"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03892512",
          "briefTitle": "Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Beni-Suef University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cognitive Dysfunction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Esmolol Hydrochloride"
            },
            {
              "name": "Dexmedetomidine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00851981",
          "briefTitle": "Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Loma Linda University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Alcoholic Hepatitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "SAMe"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00151281",
          "briefTitle": "Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Weill Medical College of Cornell University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-Hodgkin's Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PEPC"
            },
            {
              "name": "Thalidomide"
            },
            {
              "name": "Rituximab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00992719",
          "briefTitle": "Novartis H1N1 Vaccine in Pregnant Women"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Influenza"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 84,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Inactivated H1N1 Vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07020819",
          "briefTitle": "An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barr\u00e9 Syndrome (FORWARD Study)"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Annexon, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Guillain-Barre Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tanruprubart"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00955981",
          "briefTitle": "Gout Dose Response Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ardea Biosciences, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hyperuricemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 123,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "RDEA594"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03390530",
          "briefTitle": "Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2022-01-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-18"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Albert Einstein College of Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Intraventricular Hemorrhage of Prematurity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Thyroxine"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01695330",
          "briefTitle": "Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2012-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Oncotherapeutics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Myeloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Subcutaneous bortezomib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03931928",
          "briefTitle": "Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-09-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-05-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Robert Bosch Gesellschaft f\u00fcr Medizinische Forschung mbH (RBMF)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer",
            "DCIS"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 356,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "(Z)-Endoxifen supplementation according to genotype"
            },
            {
              "name": "(Z)-Endoxifen supplementation according to plasma levels"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01901328",
          "briefTitle": "Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2013-04-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-02-13"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Opioid-Induced Constipation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 49,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CB-5945"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00556465",
          "briefTitle": "Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shiraz University of Medical Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetic Nephropathy",
            "Chronic Kidney Disease",
            "Diabetes Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "N-acetylcysteine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03948867",
          "briefTitle": "Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)"
        },
        "statusModule": {
          "overallStatus": "ENROLLING_BY_INVITATION",
          "startDateStruct": {
            "date": "2019-04-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Children's Hospital Medical Center, Cincinnati"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sickle Cell Anemia in Children"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 202,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hydroxyurea"
            },
            {
              "name": "Elevated Arm TCD Examination"
            },
            {
              "name": "Normal Arm TCD Examination"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03965767",
          "briefTitle": "Does The Combined Use Of Local And Intravenous Tranexamic Acid Offer Better Surgical Field Quality During Functional Endoscopic Sinus Surgery? A Placebo-Controlled Clinical Trial"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-04-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-08-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ain Shams University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Sinus Disease",
            "Nasal Polyps"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tranexamic Acid"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01697267",
          "briefTitle": "Rituximab Vasculitis Maintenance Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-11-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cambridge University Hospitals NHS Foundation Trust"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
            "Microscopic Polyangiitis",
            "Wegener Granulomatosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 188,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rituximab"
            },
            {
              "name": "Azathioprine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00779207",
          "briefTitle": "Effect of Weight Loss and Exercise on Liver and Muscle Fat in Obese Elderly"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Washington University School of Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obesity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "weight loss and exercise"
            },
            {
              "name": "weight loss"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02729207",
          "briefTitle": "Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2016-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-12-21"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Teikoku Seiyaku Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ankle Sprain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Esflurbiprofen Hydrogel Patch"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06531707",
          "briefTitle": "Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-05-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-01-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Laboratorios Silanes S.A. de C.V."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Common Cold"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 177,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ibuprofen + Loratadine fixed dose"
            },
            {
              "name": "Ibuprofen"
            },
            {
              "name": "Loratadine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03026907",
          "briefTitle": "Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2016-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Medical Center Groningen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hand Eczema"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 116,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Alitretinoin"
            },
            {
              "name": "Azathioprine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02068092",
          "briefTitle": "Olive Oil for High Risk Breast Cancer Prevention in Women"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The Methodist Hospital Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hydroxytyrosol"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02779192",
          "briefTitle": "A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sound Pharmaceuticals, Incorporated"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Noise Induced Hearing Loss"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 180,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SPI-1005 200mg"
            },
            {
              "name": "SPI-1005 400mg"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01091636",
          "briefTitle": "Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-01-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Center, Korea"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Epithelial Ovarian Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 184,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hyperthermic Intraperitoneal Chemotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04348136",
          "briefTitle": "An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-09-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2030-03-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "JCR Pharmaceuticals Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mucopolysaccharidosis II"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "JR-141"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04313036",
          "briefTitle": "5-day Defibrotide Treatment for Hepatic SOS/VOD"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2021-03-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-05-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Loyola University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sinusoidal Obstruction Syndrome",
            "Veno-occlusive Disease",
            "Bone Marrow Transplant Complications"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Defibrotide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01821105",
          "briefTitle": "2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ohio State University Comprehensive Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent Colon Cancer",
            "Recurrent Rectal Cancer",
            "Stage IV A Bladder Cancer",
            "Stage IV A Rectal Cancer",
            "Stage IV B Colon Cancer",
            "Stage IV B Rectal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PET Scan"
            },
            {
              "name": "CT Scan"
            },
            {
              "name": "fludeoxyglucose F 18"
            },
            {
              "name": "computer-aided detection/diagnosis"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01273805",
          "briefTitle": "Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Dana-Farber Cancer Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hydroxychloroquine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00001894",
          "briefTitle": "A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1999-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Heart, Lung, and Blood Institute (NHLBI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hypertrophic Cardiomyopathy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "pacemaker implantation"
            },
            {
              "name": "percutaneous transluminal septal ablation (PTSA)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04357366",
          "briefTitle": "suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-04-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-01-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hellenic Institute for the Study of Sepsis"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID-19",
            "Virus Diseases",
            "Corona Virus Infection",
            "Lower Respiratory Tract Infection Viral"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1000,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Anakinra"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00784966",
          "briefTitle": "Islet After Kidney Transplant for Type 1 Diabetes"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2011-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Virginia Commonwealth University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Type 1 Diabetes Mellitus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "etanercept"
            },
            {
              "name": "etanercept"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06228066",
          "briefTitle": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-06-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Small Cell Carcinoma of the Bladder",
            "High Grade Neuroendocrine Tumors of the Urinary Tract"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lurbinectedin"
            },
            {
              "name": "Avelumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04950166",
          "briefTitle": "A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-11-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "OncoNano Medicine, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Peritoneal Carcinomatosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "pegsitacianine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04574856",
          "briefTitle": "Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-11-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Michigan Rogel Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Glioblastoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dose-Intensified Radiotherapy"
            },
            {
              "name": "Temozolomide"
            },
            {
              "name": "Adjuvant temozolomide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04908956",
          "briefTitle": "Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2022-08-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-10-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ETOP IBCSG Partners Foundation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "NSCLC Stage IV",
            "EGFR Gene Mutation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Osimertinib"
            },
            {
              "name": "Stereotactic Body Radiation Therapy (SBRT)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04128722",
          "briefTitle": "TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-02-14"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-02-13"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital, Tours"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lingual Microcystic Lymphatic Malformations"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sirolimus Oral Liquid Product 1mg/mL"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01439022",
          "briefTitle": "Exercise Interventions in Parkinson's Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Oxford Brookes University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 105,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Exercise Programme"
            },
            {
              "name": "Hand Writing programme"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01562951",
          "briefTitle": "Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2012-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Crohn's Disease",
            "Mucosal Inflammation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ADALIMUMAB"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00056251",
          "briefTitle": "Interstitial Cystitis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ICOS Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Interstitial Cystitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "H&P; ECG; Blood tests; voiding diary; Cystoscopy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00000451",
          "briefTitle": "Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Yale University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Alcoholism",
            "Alcohol Dependence"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 198,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "sertraline"
            },
            {
              "name": "naltrexone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00402051",
          "briefTitle": "Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-Small-Cell Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 133,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pemetrexed"
            },
            {
              "name": "Cisplatin"
            },
            {
              "name": "Carboplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01743729",
          "briefTitle": "A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-12-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-10-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shire"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dry Eye Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 720,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lifitegrast"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00176631",
          "briefTitle": "Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2007-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Rutgers, The State University of New Jersey"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "licorice root extract"
            },
            {
              "name": "docetaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01656031",
          "briefTitle": "A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Wake Forest University Health Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "clofarabine"
            },
            {
              "name": "cytarabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02303002",
          "briefTitle": "Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Revance Therapeutics, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Glabellar Frown Lines"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 268,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Botulinum Toxin Type A"
            },
            {
              "name": "Active Comparator botulinum toxin"
            },
            {
              "name": "Placebo Comparator"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00687102",
          "briefTitle": "Cognition in the Study of Tamoxifen and Raloxifene"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Wake Forest University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cognition",
            "Aging"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1498,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "tamoxifen"
            },
            {
              "name": "raloxifene"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03639922",
          "briefTitle": "Imatinib in Acute Ischaemic Stroke"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-10-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Niaz Ahmed"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Ischaemic Stroke"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1260,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Imatinib 400mg"
            },
            {
              "name": "Placebo Oral Tablet"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00290251",
          "briefTitle": "Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Leiomyoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 72,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ulipristal acetate 20 mg"
            },
            {
              "name": "ulipristal acetate 10 mg"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03125629",
          "briefTitle": "Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-05-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-11-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Stanford University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer Diagnosis",
            "Diagnostic Techniques and Procedures",
            "Diagnostic Imaging"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 53,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "F-18 FDG"
            },
            {
              "name": "Ga-68-DOTA-TATE"
            },
            {
              "name": "Positron Emission Tomography / Computed Tomography (PET/CT) Scan"
            },
            {
              "name": "Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04401202",
          "briefTitle": "Nigella Sativa in COVID-19"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-05-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "King Abdulaziz University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID-19",
            "SARS-CoV-2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 183,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nigella sativa oil"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03574402",
          "briefTitle": "Phase II Umbrella Study Directed by Next Generation Sequencing"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-07-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Guangdong Association of Clinical Trials"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 400,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Avitinib Maleate"
            },
            {
              "name": "Afatinib"
            },
            {
              "name": "Crizotinib"
            },
            {
              "name": "X-396"
            },
            {
              "name": "Chidamide"
            },
            {
              "name": "Pyrotinib Maleate"
            },
            {
              "name": "AZD3759"
            },
            {
              "name": "Pirotinib"
            },
            {
              "name": "Nimotuzumab"
            },
            {
              "name": "Pemetrexed"
            },
            {
              "name": "Cisplatin"
            },
            {
              "name": "Sintilimab"
            },
            {
              "name": "Gemcitabine"
            },
            {
              "name": "Gemcitabine"
            },
            {
              "name": "Carboplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00771602",
          "briefTitle": "Alemtuzumab + Rituximab Consolidation in CLL"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Lymphocytic Leukemia",
            "Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rituximab"
            },
            {
              "name": "Alemtuzumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03535402",
          "briefTitle": "Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-06-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gaylis, Norman B., M.D."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sarilumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05441553",
          "briefTitle": "A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shanghai Vitalgen BioPharma Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hemophilia B"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "VGB-R04"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04068753",
          "briefTitle": "Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-02-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Oklahoma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent Cervix Cancer",
            "Progressive Cervix Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Niraparib"
            },
            {
              "name": "dostarlimab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01351753",
          "briefTitle": "Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-01-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Iowa"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obesity",
            "Metabolic Syndrome X"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 136,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Metformin"
            },
            {
              "name": "Orlistat"
            },
            {
              "name": "Topiramate"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00623337",
          "briefTitle": "Ghana Newborn Home Visits Neonatal Mortality Trial"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "London School of Hygiene and Tropical Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Neonatal Mortality"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 15000,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Home visits"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00168337",
          "briefTitle": "A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Allergan"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetic Macular Edema"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 554,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dexamethasone"
            },
            {
              "name": "Sham"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01576172",
          "briefTitle": "Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-03-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-10-23"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Castration-Resistant Prostate Carcinoma",
            "Recurrent Prostate Carcinoma",
            "Stage IV Prostate Cancer AJCC v7"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 159,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Abiraterone Acetate"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Prednisone"
            },
            {
              "name": "Veliparib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00003739",
          "briefTitle": "Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1999-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2002-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Children's Oncology Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Fever, Sweats, and Hot Flashes",
            "Neutropenia",
            "Unspecified Childhood Solid Tumor, Protocol Specific"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "filgrastim"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01400139",
          "briefTitle": "Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Purdue Pharma LP"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Nonmalignant and Nonneuropathic Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 922,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hydrocodone bitartrate q24h film-coated tablets"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02076477",
          "briefTitle": "The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer\uff08NSCLC\uff09"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2014-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sichuan Cancer Hospital and Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Oligo-metastatic Stage IV Non-small Cell Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 420,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "concurrent chemoradiotherapy"
            },
            {
              "name": "Docetaxel"
            },
            {
              "name": "pemetrexed"
            },
            {
              "name": "Cisplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02392377",
          "briefTitle": "Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2015-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Case Comprehensive Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stage IB Esophageal Adenocarcinoma",
            "Stage IIA Esophageal Adenocarcinoma",
            "Stage IIB Esophageal Adenocarcinoma",
            "Stage IIIA Esophageal Adenocarcinoma",
            "Stage IIIB Esophageal Adenocarcinoma",
            "Stage IIIC Esophageal Adenocarcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Carboplatin"
            },
            {
              "name": "Oxaliplatin"
            },
            {
              "name": "Leucovorin Calcium"
            },
            {
              "name": "Fluorouracil"
            },
            {
              "name": "Radiation Therapy"
            },
            {
              "name": "Therapeutic Conventional Surgery"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03707977",
          "briefTitle": "Dual bNAb Treatment in Children"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-06-17"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-12-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ART"
            },
            {
              "name": "VRC01LS"
            },
            {
              "name": "10-1074"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01463501",
          "briefTitle": "Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2011-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Zhejiang Cancer Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Esophageal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Neoadjuvant chemoradiotherapy"
            },
            {
              "name": "Adjuvant chemoradiotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01650701",
          "briefTitle": "A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-05-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The Lymphoma Academic Research Organisation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Follicular Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1030,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rituximab"
            },
            {
              "name": "Lenalidomide"
            },
            {
              "name": "Rituximab - CHOP"
            },
            {
              "name": "Rituximab - CVP"
            },
            {
              "name": "Rituximab - Bendamustine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04283201",
          "briefTitle": "Type 2 Diabetes Mellitus Prevention Ukraine"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-02-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-11-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Komisarenko Institute of Endocrinology and Metobolism"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Impaired Fasting Glucose",
            "Impaired Glucose Tolerance",
            "Type 2 Diabetes"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Physical activity"
            },
            {
              "name": "Macronutrient modification"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05932212",
          "briefTitle": "AK104 for Recurrent or Metastatic Vulvar Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-08-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Akeso"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Vulvar Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "AK104"
            },
            {
              "name": "AK104+ Paclitaxel+Cisplatin or Carboplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02227212",
          "briefTitle": "Ease of Use and Safety of the New U300 Pen Injector in Insulin-Na\u00efve Patients With T2DM"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sanofi"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Insulin glargine U300 (new formulation of insulin glargine) HOE901"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02089919",
          "briefTitle": "Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fuda Cancer Hospital, Guangzhou"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Neoplasms, Liver"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "cancer stem cell vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00080119",
          "briefTitle": "Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2004-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infection",
            "Tuberculosis",
            "Pneumocystis Jiroveci Pneumonia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1354,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Isoniazid (INH)"
            },
            {
              "name": "Trimethoprim/Sulfamethoxazole (TMP/SMX)"
            },
            {
              "name": "Isoniazid Placebo (PL)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02971319",
          "briefTitle": "Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-11-17"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Proactina S.A."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Glioma (Diagnosis)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tc-99M-Tetrofosmin SPECT"
            },
            {
              "name": "F-18 FDG PET"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05510219",
          "briefTitle": "Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-01-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The First Affiliated Hospital with Nanjing Medical University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obinutuzumab",
            "Rapid Infusion",
            "Intravenous Infusion Reaction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "intravenous rapid infusion of obinutuzumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00718419",
          "briefTitle": "A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Waldenstrom's Macroglobulinemia",
            "Multiple Myeloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Enzastaurin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03407430",
          "briefTitle": "Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2016-01-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-06-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "UNC Lineberger Comprehensive Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer",
            "Lymphoma",
            "Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pregabalin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05337228",
          "briefTitle": "Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-08-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-02-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "HK inno.N Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parenteral Nutrition"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "IN-C006 Peri inj."
            },
            {
              "name": "RPN301"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03613428",
          "briefTitle": "Ruxolitinib Plus LVP in Patients With R/R ETP-ALL"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sichuan University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute T Cell Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ruxolitinib"
            },
            {
              "name": "Vincristine"
            },
            {
              "name": "Prednisone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03820830",
          "briefTitle": "Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-08-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-01-27"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ETOP IBCSG Partners Foundation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer Recurrent"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 405,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Palbociclib 125mg"
            },
            {
              "name": "Standard endocrine therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00555828",
          "briefTitle": "Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2008-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Angioblast Systems"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Myocardial Infarction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Allogeneic Mesenchymal Precursor Cells (MPCs)"
            },
            {
              "name": "Standard-of-care treatment with NOGA\u00ae mapping and staged injections."
            },
            {
              "name": "Allogeneic Mesenchymal Precursor Cells (MPCs)"
            },
            {
              "name": "Standard-of-care treatment with NOGA\u00ae mapping and staged injections."
            },
            {
              "name": "Allogeneic Mesenchymal Precursor Cells (MPCs)"
            },
            {
              "name": "Standard-of-care treatment with NOGA\u00ae mapping and staged injections."
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01325428",
          "briefTitle": "Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Boehringer Ingelheim"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Neoplasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Afatinib once daily (OD)"
            },
            {
              "name": "Vinorelbine Weekly"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03668665",
          "briefTitle": "Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in \"Split Wound Design\""
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2018-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "RWTH Aachen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Wound Heal"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ready Medical Post Treatment"
            },
            {
              "name": "Conventionell Treatment"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02537067",
          "briefTitle": "Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2010-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sewon Cellontech Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Defect of Articular Cartilage",
            "Degenerative Joint Disease of Ankle and/or Foot",
            "Ankle (Ligaments); Instability, Familial"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CHONDRON"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01628965",
          "briefTitle": "A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Otsuka Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 143,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SPM 962"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01959165",
          "briefTitle": "MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-11-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-08-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AstraZeneca"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ulcerative Colitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 44,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "MEDI7183 low dose"
            },
            {
              "name": "MEDI7183 medium dose"
            },
            {
              "name": "MEDI7183 high dose"
            },
            {
              "name": "Matching Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02639065",
          "briefTitle": "A Study of Durvalumab (MEDI4736) in Esophageal Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-04-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shadia Jalal, MD"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Esophageal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Durvalumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00468767",
          "briefTitle": "Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Advanz Pharma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Atrial Fibrillation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 356,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vernakalant Injection 20 mg/mL"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00146367",
          "briefTitle": "Evaluation of the Active Living Every Day Exercise Program for People With Arthritis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centers for Disease Control and Prevention"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 355
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Active Living Every Day"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01489267",
          "briefTitle": "A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2011-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "General Hospital of Chinese Armed Police Forces"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hereditary Cerebellar Ataxia."
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "stem cell transplantation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05668767",
          "briefTitle": "Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2022-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Beijing Chest Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Extensive-stage Small-cell Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Surufatinib Durvalizumab EP/EC"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01188200",
          "briefTitle": "Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Abbott Nutrition"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 168,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Experimental nutritional formula #M979"
            },
            {
              "name": "Standard food"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02525107",
          "briefTitle": "Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2015-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sultan Qaboos University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sickle Cell Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 280,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Omega-3 capsules"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Omega-3 capsules"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02642107",
          "briefTitle": "Individualized Elective Neck Irradiation Based on MRI in NPC Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nasopharyngeal Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 446,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Elective neck irradiation"
            },
            {
              "name": "Whole neck irradiation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00304005",
          "briefTitle": "VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Vion Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Leukemia",
            "Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "laromustine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01239394",
          "briefTitle": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Massachusetts General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Follicular Lymphoma",
            "Marginal Zone Lymphoma",
            "Small Lymphocytic Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ofatumumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03172494",
          "briefTitle": "A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-05-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-06-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novo Nordisk A/S"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes",
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 720,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Insulin degludec/liraglutide"
            },
            {
              "name": "Insulin degludec"
            },
            {
              "name": "Liraglutide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00190866",
          "briefTitle": "Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Fibromyalgia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 210
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Duloxetine"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06536166",
          "briefTitle": "Ruxolitinib Treatment in Inclusion Body Myositis"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-05-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-06-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assistance Publique - H\u00f4pitaux de Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Inclusion Body Myositis, Sporadic"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ruxolitinib"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00101166",
          "briefTitle": "Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H. Lee Moffitt Cancer Center and Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma (Skin)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bystander-Based Autologous Tumor Cell Vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04693351",
          "briefTitle": "Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-01-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-04-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Biohaven Pharmaceuticals, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obsessive-Compulsive Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 589,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Troriluzole"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01824251",
          "briefTitle": "Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Nihon Pharmaceutical Co., Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Inflammatory Demyelinating Polyneuropathy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 49,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NPB-01"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00737529",
          "briefTitle": "A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The \"EMERGE\" Trial"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-12-22"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-04-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Celgene"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mantle Cell Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 134,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "lenalidomide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01739231",
          "briefTitle": "Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "PATH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diarrhea"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 81,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ACE527"
            },
            {
              "name": "dmLT"
            },
            {
              "name": "CeraVacx placebo"
            },
            {
              "name": "H10407 challenge strain"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00405353",
          "briefTitle": "Testosterone Treatment for Multiple Sclerosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2002-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of California, Los Angeles"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Androgel 10 grams of gel containing 100 mg of testosterone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02420353",
          "briefTitle": "Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Michigan"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rupture of Anterior Cruciate Ligament"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Somatropin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01185353",
          "briefTitle": "A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Arthritis, Rheumatoid"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 301,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LY3009104"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Methotrexate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01924845",
          "briefTitle": "BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2014-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-09-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "BioMarin Pharmaceutical"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Late-onset Pompe Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BMN 701"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04221672",
          "briefTitle": "The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-11-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shanghai Zhongshan Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Terlipressin Adverse Reaction",
            "Ascites Hepatic",
            "Liver Failure",
            "Acute Kidney Injury"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 86,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Terlipressin plus standard care"
            },
            {
              "name": "Standard care"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02057172",
          "briefTitle": "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hanmi Pharmaceutical Company Limited"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Type 2 Diabetes"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 254,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "HM11260C"
            },
            {
              "name": "liraglutide"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03713372",
          "briefTitle": "Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-11-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-02-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sinocelltech Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Head and Neck Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Anti-EGFR monoclonal antibody"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00450372",
          "briefTitle": "Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Miami"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma (Skin)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 38,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ADI-PEG-20"
            },
            {
              "name": "Pharmacology Studies"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05856695",
          "briefTitle": "Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2023-11-17"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Intergroupe Francophone de Cancerologie Thoracique"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Small Cell Lung Cancer Extensive Stage"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 67,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Carboplatin + Paclitaxel + Durvalumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04236739",
          "briefTitle": "Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-07-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "R.J.H. Custers"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cartilage Damage"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Instant MSC Product accompanying Autologous Chondron Transplantation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05509777",
          "briefTitle": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-03-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Crohn's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Mirikizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05437575",
          "briefTitle": "Prehospital Analgesia INtervention Trial (PAIN)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-11-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Jason Sperry"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Traumatic Injury"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 994,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ketamine Hydrochloride"
            },
            {
              "name": "Fentanyl Citrate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02387957",
          "briefTitle": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin\u00ae, Lucentis\u00ae, or Eylea\u00ae (Anti-VEGF Therapy) Administered in Combination With Fovista\u00ae (Anti-PDGF BB Pegylated Aptamer)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2016-04-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ophthotech Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Age-Related Macular Degeneration"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fovista\u00ae"
            },
            {
              "name": "bevacizumab"
            },
            {
              "name": "ranibizumab"
            },
            {
              "name": "aflibercept"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01003301",
          "briefTitle": "The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Johns Hopkins University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cat Allergy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Omalizumab"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00872612",
          "briefTitle": "Trial for the Diagnosis of Sarcoidosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Leiden University Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sarcoidosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 304,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "EUS-FNA/EBUS-TBNA + BAL"
            },
            {
              "name": "EBB + TBLB + BAL"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00589212",
          "briefTitle": "GliaSite 1-3 Mets Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hologic, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Brain Metastases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GliaSite Radiation Therapy System"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00016081",
          "briefTitle": "Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1998-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2003-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fred Hutchinson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ]
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ribavirin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06742281",
          "briefTitle": "A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-12-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "CyanVac LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID-19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10016,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CVXGA (CVXGA50)"
            },
            {
              "name": "COMIRNATY\u00ae"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00110019",
          "briefTitle": "Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mucosal Melanoma",
            "Recurrent Melanoma",
            "Stage IIIA Skin Melanoma",
            "Stage IIIB Skin Melanoma",
            "Stage IIIC Skin Melanoma",
            "Stage IV Skin Melanoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 823,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Carboplatin"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Pharmacological Study"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Sorafenib Tosylate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03564119",
          "briefTitle": "A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-06-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-06-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sol-Gel Technologies, Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Papulopustular Rosacea"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 372,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "S5G4T-1"
            },
            {
              "name": "S5G4T-2"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06530719",
          "briefTitle": "A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2024-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Jin Ying"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Neoplasms",
            "Lung Cancer, Nonsmall Cell"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 54,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Osimertinib mesylate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06277219",
          "briefTitle": "A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-06-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Latticon Antibody Therapeutics, Inc"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Solid Tumor"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LAT010"
            },
            {
              "name": "LAT010 + ICI"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00661219",
          "briefTitle": "Depression Related Improvement With Vardenafil for Erectile Response"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2002-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2003-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bayer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Erectile Dysfunction",
            "Depression"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 280,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Levitra (Vardenafil, BAY38-9456)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01526330",
          "briefTitle": "Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Yuhan Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Degenerative Disc Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 48,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "YH14618"
            },
            {
              "name": "YH14618"
            },
            {
              "name": "YH14618"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05771428",
          "briefTitle": "Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-04-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-08-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AbbVie"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Alzheimer's Disease (AD)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 263,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ABBV-552"
            },
            {
              "name": "Placebo for ABBV-552"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00112528",
          "briefTitle": "Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alliance for Clinical Trials in Oncology"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 53,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "bevacizumab"
            },
            {
              "name": "gemcitabine hydrochloride"
            },
            {
              "name": "oxaliplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04912765",
          "briefTitle": "Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2021-04-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Centre, Singapore"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma",
            "Hepatocellular Cancer",
            "Colorectal Cancer",
            "Colorectal Carcinoma",
            "Liver Metastases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Neoantigen Dendritic Cell Vaccine"
            },
            {
              "name": "Nivolumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03365765",
          "briefTitle": "mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-02-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Huashan Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Apatinib"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Apatinib"
            },
            {
              "name": "Oxaliplatin"
            },
            {
              "name": "5-fluorouracil"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02085265",
          "briefTitle": "Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2014-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-02-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sunnybrook Health Sciences Centre"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Alzheimer's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Perindopril"
            },
            {
              "name": "Telmisartan"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04595565",
          "briefTitle": "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-10-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-03-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GBG Forschungs GmbH"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HER2-negative Breast Cancer",
            "Triple Negative Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1332,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Capecitabine"
            },
            {
              "name": "Carboplatin"
            },
            {
              "name": "Cisplatin"
            },
            {
              "name": "Sacituzumab govitecan"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06186700",
          "briefTitle": "Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-12-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mansoura University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer Female",
            "Breast Cancer Patients",
            "Neoadjuvant Therapy",
            "Doxorubicin",
            "Taxane-induced Peripheral Neuropathy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pentoxifylline 400mg plus chemotherapy"
            },
            {
              "name": "Chemotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01739400",
          "briefTitle": "Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2013-09-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-01-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Actelion"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pulmonary Arterial Hypertension"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 217,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Macitentan 10 mg tablet, once daily."
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00035100",
          "briefTitle": "EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2003-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ovarian Neoplasms",
            "Peritoneal Neoplasms",
            "Fallopian Tube Neoplasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "epothilone b"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04539600",
          "briefTitle": "Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-11-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-07-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hypopharyngeal Cancer",
            "Immunotherapy",
            "Induction Chemotherapy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 23,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Camrelizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04219007",
          "briefTitle": "Vosoritide for Selected Genetic Causes of Short Stature"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-08-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Andrew Dauber"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Short Stature"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vosoritide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03283007",
          "briefTitle": "Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-10-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-03-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assistance Publique - H\u00f4pitaux de Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung-transplant Recipients"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nintedanib"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03410992",
          "briefTitle": "A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-02-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-12-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "UCB Biopharma SRL"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Plaque Psoriasis",
            "Moderate to Severe Chronic Plaque Psoriasis",
            "Psoriatic Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 435,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bimekizumab"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01104792",
          "briefTitle": "Long-term Study of Cariprazine in Patients With Schizophrenia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-05-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-01-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Forest Laboratories"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Schizophrenia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 752,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cariprazine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01203436",
          "briefTitle": "Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1994-02"
          },
          "primaryCompletionDateStruct": {
            "date": "1999-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "NICHD Neonatal Research Network"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Infant, Newborn",
            "Infant, Low Birth Weight",
            "Infant, Small for Gestational Age",
            "Infant, Premature",
            "Retinopathy of Prematurity",
            "Blindness"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 649,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Supplemental Oxygen Management"
            },
            {
              "name": "Conventional Oxygen Management"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01037036",
          "briefTitle": "A Study of the L-PPDS With Adjunctive Xalatan\u00ae Eye Drops in Subjects With OH or OAG"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mati Therapeutics Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ocular Hypertension",
            "Open-Angle Glaucoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Latanoprost Punctal Plug Delivery System"
            },
            {
              "name": "Xalatan"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01011036",
          "briefTitle": "Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Insel Gruppe AG, University Hospital Bern"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "clobazam"
            },
            {
              "name": "clonazepam"
            },
            {
              "name": "tolterodine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05601336",
          "briefTitle": "of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-01-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-07-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Beni-Suef University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "PCO"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dapagliflozin 5 MG"
            },
            {
              "name": "Metformin Hydrochloride 1000 MG"
            },
            {
              "name": "Dapagliflozin/Metformin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02756611",
          "briefTitle": "A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-06-22"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-04-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AbbVie"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Lymphocytic Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 258,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Venetoclax"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06570811",
          "briefTitle": "Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Damanhour University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer",
            "Chemotherapeutic Toxicity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "Coenzyme Q10 200mg twice daily"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03040011",
          "briefTitle": "Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-06-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-04-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lauren Giugale, MD"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pelvic Organ Prolapse",
            "Surgery",
            "Postoperative Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 79,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dexamethasone"
            },
            {
              "name": "Bupivacaine"
            },
            {
              "name": "Bilateral Pudendal Nerve Block"
            },
            {
              "name": "Bilateral Levator Ani Muscle Injection"
            },
            {
              "name": "Saline"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04513171",
          "briefTitle": "Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-12-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-06-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Xiamen Amoytop Biotech Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Growth Hormone Deficiency"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 434,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Y-shape pegylated somatropin"
            },
            {
              "name": "Y-shape pegylated somatropin"
            },
            {
              "name": "Y-shape pegylated somatropin"
            },
            {
              "name": "Norditropin\u00ae"
            },
            {
              "name": "Y-shape pegylated somatropin"
            },
            {
              "name": "Norditropin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03791905",
          "briefTitle": "PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-01-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mian XI"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Neoplasm, Esophageal",
            "Squamous Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 216,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Cisplatin"
            },
            {
              "name": "Oxaliplatin"
            },
            {
              "name": "5-FU"
            },
            {
              "name": "Leucovorin"
            },
            {
              "name": "Intensity-modulated radiotherapy"
            },
            {
              "name": "PET"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03466866",
          "briefTitle": "Reducing Emergency Diabetes Care for Older African Americans"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-01-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Thomas Jefferson University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 156,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PREVENT"
            },
            {
              "name": "EUC (Enhanced Usual Care)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02642094",
          "briefTitle": "Aging Mammary Stem Cells and Breast Cancer Prevention"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2016-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-03-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "LuZhe Sun"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer of Breast"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rapamycin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07073794",
          "briefTitle": "Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-08-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-08-27"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mayo Clinic"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Biochemically Recurrent Prostate Carcinoma",
            "Locally Advanced Prostate Carcinoma",
            "Metastatic Prostate Carcinoma",
            "Stage III Prostate Cancer AJCC v8",
            "Stage IV Prostate Cancer AJCC v8"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cancer Therapeutic Procedure"
            },
            {
              "name": "Cancer Therapeutic Procedure"
            },
            {
              "name": "Health Care Delivery"
            },
            {
              "name": "Questionnaire Administration"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06948422",
          "briefTitle": "A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-04-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hypertension"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 974,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Orforglipron"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01890122",
          "briefTitle": "Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Takeda"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 647,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Alogliptin"
            },
            {
              "name": "Metformin HCl"
            },
            {
              "name": "Alogliptin and Metformin Fixed-Dose Combination (FDC)"
            },
            {
              "name": "Alogliptin Placebo"
            },
            {
              "name": "Metformin Placebo"
            },
            {
              "name": "Alogliptin and Metformin FDC Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00324922",
          "briefTitle": "Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-05-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-05-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Washington"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Osteomyelitis",
            "Methicillin-resistant Staphylococcus Aureus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "trimethoprim-sulfamethoxazole"
            },
            {
              "name": "vancomycin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01354522",
          "briefTitle": "TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Peking Union Medical College Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 204,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Docetaxel, Doxorubicin, Cyclophosphamide"
            },
            {
              "name": "Docetaxel, Cyclophosphamide, Capecitabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04065529",
          "briefTitle": "Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-09-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-06-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ferrer Internacional S.A."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diarrhea"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation"
            },
            {
              "name": "placebo + ORS + Zinc supplementation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06880029",
          "briefTitle": "Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-09-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Triple Negative Breast Cancer (TNBC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Morning pembrolizumab infusions"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00518531",
          "briefTitle": "Denosumab Adherence Preference Satisfaction Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-09-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-06-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Amgen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Osteoporosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 250,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "alendronate"
            },
            {
              "name": "denosumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00970931",
          "briefTitle": "Hypertension Prevention in Pre-Hypertensive Individuals"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hospital de Clinicas de Porto Alegre"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pre-hypertension",
            "Hypertension",
            "Cardiovascular Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 730,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Chlorthalidone plus amiloride"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05676931",
          "briefTitle": "Study With Various Immunotherapy Treatments in Participants With Lung Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2023-02-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gilead Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Non-Small Cell Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 400,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Domvanalimab"
            },
            {
              "name": "Quemliclustat"
            },
            {
              "name": "Zimberelimab"
            },
            {
              "name": "Docetaxel"
            },
            {
              "name": "Platinum-Based Doublet"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00328731",
          "briefTitle": "Milk ALLERGY ELIMINATION THROUGH NAET\u00ae (Nambudripad's Allergy Elimination Techniques)."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Nambudripad's Allergy Research Foundation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Milk Allergy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 26
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Procedure"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04115631",
          "briefTitle": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-12-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ECOG-ACRIN Cancer Research Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Liver Lymphoma",
            "Mantle Cell Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 360,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Acalabrutinib"
            },
            {
              "name": "Bendamustine"
            },
            {
              "name": "Bendamustine Hydrochloride"
            },
            {
              "name": "Cytarabine"
            },
            {
              "name": "Rituximab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04036253",
          "briefTitle": "Study of HEMAX PFS Versus EPREX/ ERYPO\u00ae in Predialysis Chronic Kidney Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-02-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-06-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bio Sidus SA"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anemia of Chronic Kidney Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Erythropoietin alfa"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01588353",
          "briefTitle": "Collagenase Option for Reduction of Dupuytren's Contracture in Japan"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Asahi Kasei Pharma Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dupuytren's Contracture"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 104,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Collagenase Clostridium Histolyticum"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05818137",
          "briefTitle": "A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2023-05-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-03-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merck Sharp & Dohme LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pulmonary Arterial Hypertension"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sotatercept"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00364845",
          "briefTitle": "STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2006-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Amgen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anemia",
            "Chronic Kidney Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Darbepoetin alfa"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03349645",
          "briefTitle": "Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2017-12-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-10-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ampio Pharmaceuticals. Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Severe Osteoarthritis of the Knee"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 94,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "4 mL injection of AMPION\u2122"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01534845",
          "briefTitle": "Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2012-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Jong Hoon Kim"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anaplastic Glioma of Brain",
            "Loss of Chromosomes 1p/19q"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Temozolomide (Temodal)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04462445",
          "briefTitle": "Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-06-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-02-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Renal Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pazopanib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00147472",
          "briefTitle": "Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ontario Clinical Oncology Group (OCOG)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer of the Head and Neck"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 400,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PET scan in addition to conventional CT imaging"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05118672",
          "briefTitle": "Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2025-03-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-08-26"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eurofarma Laboratorios S.A."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cold",
            "Flu Symptom"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 567,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04246372",
          "briefTitle": "Tofacitinib for Immune Skin Conditions in Down Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-10-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-10-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Colorado, Denver"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Down Syndrome",
            "Alopecia Areata",
            "Atopic Dermatitis / Eczema",
            "Hidradenitis Suppurativa",
            "Vitiligo",
            "Psoriasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tofacitinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03037372",
          "briefTitle": "Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2017-06-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Makerere University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 320,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ART, Atorvastatin"
            },
            {
              "name": "ART, Rosuvastatin"
            },
            {
              "name": "ART, No statin"
            },
            {
              "name": "Healthy-HIV-negative"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03632772",
          "briefTitle": "Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-07-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Buddhist Tzu Chi General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Overactive Bladder Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 130,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Solifenacin 5Mg"
            },
            {
              "name": "Mirabegron 50 MG"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01646645",
          "briefTitle": "Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-07-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cytomegalovirus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CMV-pp65 CTLs"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00376272",
          "briefTitle": "GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gruppo di Ricerca GISSI"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Atrial Fibrillation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1442,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Valsartan"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01617772",
          "briefTitle": "Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2016-01-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tehran University of Medical Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-alcoholic Steatohepatitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 440,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Atorvastatin"
            },
            {
              "name": "L-Carnitine"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00493272",
          "briefTitle": "Dilutional Coagulopathy in Patients Undergoing Elective Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Christian Fenger-Eriksen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Blood Coagulation Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fibrinogen"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05326672",
          "briefTitle": "Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Peking University People's Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Atopic Dermatitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 240,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Benvitimod Cream"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03361839",
          "briefTitle": "Endometrial Receptivity in Patients With Recurrent Implantation Failure as a Preparatory Step for PET"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2017-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cairo University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "RIF , Endometrial Receptivity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "endometrial biopsy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04249739",
          "briefTitle": "Pembrolizumab + Capecitabine\uff0fOxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-09-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-02-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Samsung Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gastric Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 93,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pembrolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06662539",
          "briefTitle": "Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2024-12-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Zealand Pharma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obesity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 494,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Petrelintide"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00046839",
          "briefTitle": "Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2002-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Radiation Therapy Oncology Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "celecoxib"
            },
            {
              "name": "radiation therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05634577",
          "briefTitle": "A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2023-03-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-07-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Adrenocortical Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Mitotane"
            },
            {
              "name": "Pembrolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00069875",
          "briefTitle": "A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 195
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gemcitabine"
            },
            {
              "name": "LY293111"
            },
            {
              "name": "cisplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02546401",
          "briefTitle": "Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital, Brest"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Type 1"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Insulin Aspart"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00981201",
          "briefTitle": "Celecoxib as a Chemopreventive Agent in Current and Former Smokers"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Smoking",
            "Prevention"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 219,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Celecoxib"
            },
            {
              "name": "Celecoxib"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01440101",
          "briefTitle": "Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Biogen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 106,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Natalizumab (BG00002)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01336712",
          "briefTitle": "Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Northside Hospital, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Leukemia",
            "Acute Leukemia",
            "Hodgkin's Disease",
            "Non-Hodgkin's Lymphoma",
            "Myelodysplastic Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Peripheral Blood Stem Cell Transplant"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03044912",
          "briefTitle": "Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2015-11-16"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-02-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Buddhist Tzu Chi General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Overactive Bladder Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 574,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "mirabegron"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01724112",
          "briefTitle": "Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "BlackThorn Therapeutics, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Major Depressive Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 136,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LY2940094"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04612712",
          "briefTitle": "A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2021-01-19"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Suzhou Zelgen Biopharmaceuticals Co.,Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Gastrointestinal Tumors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Donafenib Tosilate Tablets"
            },
            {
              "name": "KN046 Injection"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04374019",
          "briefTitle": "Novel Agents for Treatment of High-risk COVID-19 Positive Patients"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2020-05-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-21"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Susanne Arnold"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID",
            "Sars-CoV2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ivermectin"
            },
            {
              "name": "Camostat Mesilate"
            },
            {
              "name": "Artemesia annua"
            },
            {
              "name": "Artesunate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03054519",
          "briefTitle": "Improve PAD PERformance With METformin"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2017-05-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-08-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Northwestern University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Peripheral Artery Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 203,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Metformin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04496219",
          "briefTitle": "Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-01-22"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-08-16"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fred Hutchinson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Bladder Urothelial Carcinoma In Situ",
            "Recurrent Bladder Urothelial Carcinoma",
            "Stage 0a Bladder Cancer AJCC v8",
            "Stage 0is Bladder Cancer AJCC v8",
            "Stage I Bladder Cancer AJCC v8",
            "Superficial Bladder Urothelial Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Acupuncture Therapy"
            },
            {
              "name": "BCG Solution"
            },
            {
              "name": "Best Practice"
            },
            {
              "name": "Quality-of-Life Assessment"
            },
            {
              "name": "Questionnaire Administration"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03745430",
          "briefTitle": "RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-01-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-06-17"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hellenic Cooperative Oncology Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Adenocarcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ramucirumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03941730",
          "briefTitle": "Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-08-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-07-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mayo Clinic"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Triple-Negative Breast Carcinoma",
            "Anatomic Stage III Breast Cancer AJCC v8",
            "Anatomic Stage IV Breast Cancer AJCC v8",
            "Metastatic Triple-Negative Breast Carcinoma",
            "Recurrent Breast Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Biopsy"
            },
            {
              "name": "Computed Tomography"
            },
            {
              "name": "Magnetic Resonance Imaging"
            },
            {
              "name": "Positron Emission Tomography"
            },
            {
              "name": "Therapeutic Estradiol"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01119430",
          "briefTitle": "Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2004-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Major Depression"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "DU125530"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02213328",
          "briefTitle": "Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-03-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 148,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Truvada"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03355365",
          "briefTitle": "Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-09-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-02-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tisch Multiple Sclerosis Research Center of New York"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Intrathecal MSC-NP injection"
            },
            {
              "name": "Intrathecal saline injection"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02675465",
          "briefTitle": "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-07-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Amicus Therapeutics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pompe Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ATB200"
            },
            {
              "name": "AT2221"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01155700",
          "briefTitle": "Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Allergic Asthma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "omalizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00040807",
          "briefTitle": "Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2002-11-19"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eastern Cooperative Oncology Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Head and Neck Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ]
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "docetaxel"
            },
            {
              "name": "irinotecan hydrochloride"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00228007",
          "briefTitle": "Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2000-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Butler Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Depression",
            "Substance-Related Disorders",
            "HIV Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 265
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Antidepressant Medication"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01583192",
          "briefTitle": "Chloridehexidine Versus Povidine Jodine Both Soluted in Alcohol in Forefoot Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "St. Antonius Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hallux Valgus",
            "Arthritis of the First Metatarsophalangeal Joint"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "skin preparation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06033092",
          "briefTitle": "Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2024-06-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "European Institute of Oncology"
          }
        },
        "conditionsModule": {
          "conditions": [
            "BRCA Mutation",
            "PALB2 Gene Mutation",
            "Ductal Carcinoma in Situ",
            "Lobular Carcinoma in Situ",
            "ATM Gene Mutation",
            "CHEK2 Gene Mutation",
            "CDH1 Gene Mutation",
            "RAD51C Gene Mutation",
            "RAD51D Gene Mutation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tamoxifen 10 mg Tablet"
            },
            {
              "name": "Intermittent caloric restriction"
            },
            {
              "name": "Step counter Device"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03554642",
          "briefTitle": "Walkbot Robotic Training for Improvement in Gait"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Burke Medical Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ischemic Stroke",
            "Gait, Hemiplegic"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Walkbot"
            },
            {
              "name": "Physical Therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01318642",
          "briefTitle": "Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2012-05-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-11-27"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "NantBioScience, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Adenocarcinoma of the Pancreas",
            "Locally Advanced",
            "Unresectable"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gemcitabine"
            },
            {
              "name": "AMG 479"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00653042",
          "briefTitle": "Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Scios, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Coronary Artery Bypass Surgery",
            "Coronary Heart Disease",
            "Coronary Artery Bypass Grafting",
            "Cardiopulmonary Bypass",
            "Ischemic Heart Disease",
            "Congestive Heart Failure"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 305,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nesiritide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01888042",
          "briefTitle": "Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gustave Roussy, Cancer Campus, Grand Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Everolimus"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00336986",
          "briefTitle": "Efficacy Study of IL-21 to Treat Metastatic Melanoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novo Nordisk A/S"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer",
            "Malignant Melanoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "recombinant interleukin-21"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00258986",
          "briefTitle": "Efficacy Study Comparing Hand-assisted Laparoscopic and Mini-incision Muscle Splitting Incision Living Donor Nephrectomy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Medical Center Groningen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Living Donors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Living donornephrectomy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00869986",
          "briefTitle": "A Study for Patients With Relapsing Remitting Multiple Sclerosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Relapsing Remitting Multiple Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 218,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "dirucotide"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04122170",
          "briefTitle": "Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-09-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "SFJ Pharmaceuticals, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Healthy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 207,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ticagrelor Oral Tablet - Pre-Treatment"
            },
            {
              "name": "Aspirin (ASA) Oral Tablet - Pre-Treatment"
            },
            {
              "name": "Bentracimab (PB2452) Infusion"
            },
            {
              "name": "Placebo (0.9% Sodium chloride) infusion"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03598270",
          "briefTitle": "Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-11-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-08-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent Ovarian Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 417,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "Carboplatin"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Niraparib"
            },
            {
              "name": "Gemcitabine"
            },
            {
              "name": "Pegylated liposomal doxorubicin (PLD)"
            },
            {
              "name": "Atezolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04662073",
          "briefTitle": "COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2021-04-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-06-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Stanford University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Covid19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Camostat"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00368069",
          "briefTitle": "A Study to Look at the Efficacy and Safety of Keppra\u00ae Extended Release Formulation - XR"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "UCB Pharma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Epilepsy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 158,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Keppra\u00ae extended release formulation - XR"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01237041",
          "briefTitle": "Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-10-17"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obesity",
            "Short Stature",
            "Growth Hormone Deficiency"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Niacin First"
            },
            {
              "name": "Placebo First"
            },
            {
              "name": "Dose-Establishing Study 1 Niacin 250mg"
            },
            {
              "name": "Dose-Establishing Study 1 Niacin 500mg"
            },
            {
              "name": "Dose-Establishing Study 2 Niacin 500mg"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01984541",
          "briefTitle": "To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Laboratorios Leti, S.L."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Allergy to Pollen"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Artemisia vulgaris"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03320941",
          "briefTitle": "A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-12-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-07-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obesity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 126,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LIK066"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02147054",
          "briefTitle": "A Pilot Study Using Rocuronium to Prevent Intermediate Syndrome After Organophosphorus Insecticide Poisoning"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Edinburgh"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Organophosphate Poisoning"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rocuronium"
            },
            {
              "name": "Sugammadex"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02239354",
          "briefTitle": "A Safety, Tolerability, and Efficacy Study of VC-01\u2122 Combination Product in Subjects With Type I Diabetes Mellitus"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2014-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ViaCyte"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Type 1 Diabetes Mellitus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "VC-01\u2122 Combination Product"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02807805",
          "briefTitle": "Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2016-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mamta Parikh"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Prostate Carcinoma",
            "Recurrent Prostate Carcinoma",
            "Stage IV Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Abiraterone Acetate"
            },
            {
              "name": "Niclosamide"
            },
            {
              "name": "Prednisone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01534494",
          "briefTitle": "Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of New Mexico"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Alcohol Dependence"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Psilocybin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05214794",
          "briefTitle": "An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-04-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Maruho Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Systemic Sclerosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "nemolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03165994",
          "briefTitle": "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-10-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-11-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Apexigen America, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Esophageal Cancer",
            "GastroEsophageal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "APX005M"
            },
            {
              "name": "Radiation Therapy"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Carboplatin"
            },
            {
              "name": "Surgical resection of tumor"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04124666",
          "briefTitle": "Clinical Study of Granulocyte Infusion for Advanced Cancer"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2019-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shanghai East Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Granulocytes"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02314156",
          "briefTitle": "Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Northwestern University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "BRCA1 Mutation Carrier",
            "BRCA2 Mutation Carrier",
            "Ductal Breast Carcinoma In Situ",
            "Lobular Breast Carcinoma In Situ",
            "Stage 0 Breast Cancer",
            "Stage IA Breast Cancer",
            "Stage IB Breast Cancer",
            "Stage IIA Breast Cancer",
            "Stage IIB Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Telapristone Acetate"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Telapristone Acetate"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Laboratory Biomarker Analysis"
            },
            {
              "name": "Questionnaire Administration"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00084656",
          "briefTitle": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-05-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-10-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bristol-Myers Squibb"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Intraocular Melanoma",
            "Melanoma (Skin)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 77,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ipilimumab"
            },
            {
              "name": "Tyrosinase/gp100/MART-1 Peptides"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02720822",
          "briefTitle": "Breathlessness Exertion and Morphine Sulphate"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-08-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Flinders University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Obstructive Pulmonary Disease",
            "Dyspnea"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 171,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "Morphine Sulfate"
            },
            {
              "name": "Plus laxative (Docusate with senna)"
            },
            {
              "name": "Plus placebo laxative"
            },
            {
              "name": "FitBit charge HR (Accelerometer)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01227551",
          "briefTitle": "A Study of Intratumoral CAVATAK\u2122 in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-12-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-04-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Viralytics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malignant Melanoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Coxsackievirus A21 (CVA21)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04858451",
          "briefTitle": "COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2021-03-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Thirty Respiratory Limited"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COPD",
            "Bronchiectasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 88,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "RESP301"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02008929",
          "briefTitle": "to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Samsung Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "MG4101"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00363831",
          "briefTitle": "Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2006-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The University of Hong Kong"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nasopharyngeal Neoplasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Oxaliplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01984931",
          "briefTitle": "Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2013-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "CM Chungmu Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nausea",
            "Vomiting"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)"
            },
            {
              "name": "Metoclopramide hydrochloride monohydrate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05666453",
          "briefTitle": "A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2022-04-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-05-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "SK Plasma Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Liver Transplantation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LIV-GAMMA SN Inj."
            },
            {
              "name": "No intervention"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04584853",
          "briefTitle": "PreOperative Endocrine Therapy for Individualised Care With Abemaciclib"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-12-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2030-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Institute of Cancer Research, United Kingdom"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer Female"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 2032,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Abemaciclib"
            },
            {
              "name": "Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05271253",
          "briefTitle": "Comparison Between Different Anaesthesia Techniques Protecting Renal Function in Children Undergoing Radicle Nephrectomy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-04-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-11-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alexandria University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Renal Injury",
            "Child, Only"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 75,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dexmedetomidine"
            },
            {
              "name": "bupivacaine"
            },
            {
              "name": "normal Saline"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07034053",
          "briefTitle": "Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-10-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ekaterina Laukhtina"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Urothelial Carcinoma",
            "Metastatic Urothelial Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Clofarabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02574637",
          "briefTitle": "Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2016-01-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-07-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AstraZeneca"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Crohn's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Brazikumab IV Infusion"
            },
            {
              "name": "Brazikumab SC Injection"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01433172",
          "briefTitle": "Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-03-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-01-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H. Lee Moffitt Cancer Center and Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Cancer",
            "Adenocarcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 73,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Phase I - GM.CD40L.CCL21 Vaccinations"
            },
            {
              "name": "Phase II - GM.CD40L cells Vaccinations"
            },
            {
              "name": "Phase II - GM.CD40L.CCL21 Vaccinations"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03117972",
          "briefTitle": "Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2017-08-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-08-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centre Hospitalier Universitaire de Besancon"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Colorectal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "FOLFOXIRI"
            },
            {
              "name": "FOLFOX"
            },
            {
              "name": "FOLFIRI"
            },
            {
              "name": "Bevacizumab"
            },
            {
              "name": "LV5FU2"
            },
            {
              "name": "Capecitabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00757172",
          "briefTitle": "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alliance for Clinical Trials in Oncology"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Adenocarcinoma of the Gastroesophageal Junction",
            "Esophageal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "panitumumab"
            },
            {
              "name": "cisplatin"
            },
            {
              "name": "docetaxel"
            },
            {
              "name": "neoadjuvant therapy"
            },
            {
              "name": "therapeutic conventional surgery"
            },
            {
              "name": "radiation therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03840772",
          "briefTitle": "Eribulin in Advanced Solitary Fibrous Tumor"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-07-17"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-09-18"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Italian Sarcoma Group"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Solitary Fibrous Tumor"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Eribulin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03575195",
          "briefTitle": "Microbiota Intervention to Change the Response of Parkinson's Disease"
        },
        "statusModule": {
          "overallStatus": "SUSPENDED",
          "startDateStruct": {
            "date": "2019-07-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of California, San Francisco"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 86,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rifaximin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03954639",
          "briefTitle": "Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2020-06-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pacira Pharmaceuticals, Inc"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Bunion",
            "Metatarsophalangeal Fusion",
            "Midfoot Fusion",
            "Hindfoot Fusion",
            "Total Ankle Arthroplasty",
            "Forefoot Surgery"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "EXPAREL 13.3Mg/mL Suspension for Injection"
            },
            {
              "name": "Bupivacaine Hydrochloride"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03702777",
          "briefTitle": "A Study of ASP8302 in Participants With Underactive Bladder"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-11-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-04-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Astellas Pharma Europe B.V."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Underactive Bladder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 135,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ASP8302"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03696277",
          "briefTitle": "SAbR For Oligo-Progressive Renal Cell Cancer."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-10-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-01-23"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Texas Southwestern Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Oligoprogressive Renal Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Stereotactic ablative body radiation (SABR)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05249712",
          "briefTitle": "Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-01-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-01-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Darolutamide 300 mg"
            },
            {
              "name": "Androgen deprivation therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00933712",
          "briefTitle": "Dermacyd Silver Floral (Lactic Acid) - Compatibility."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sanofi"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hygiene"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 55,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LACTIC ACID(ND)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05734612",
          "briefTitle": "The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-12-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-03-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Indonesia University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Reperfusion Injury, Myocardial"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Colchicine"
            },
            {
              "name": "Placebo (lactose)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05213312",
          "briefTitle": "Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-06-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-11-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shanghai Zhongshan Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Esophageal Squamous Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nivolumab"
            },
            {
              "name": "Cisplatin"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "5Fluorouracil"
            },
            {
              "name": "Esophagectomy (minimally invasive)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05075681",
          "briefTitle": "Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2021-11-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chinese PLA General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Peripheral Blood Stem Cell Transplantation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02905019",
          "briefTitle": "A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-12-21"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Oxford"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malaria"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "R21 with Matrix-M1"
            },
            {
              "name": "ChAd63 ME-TRAP"
            },
            {
              "name": "MVA ME-TRAP"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00169481",
          "briefTitle": "A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Streptococcal Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 689,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pneumococcal (vaccine)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05039619",
          "briefTitle": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-05-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hoffmann-La Roche"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lupus Nephritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Obinutuzumab"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Mycophenolate Mofetil"
            },
            {
              "name": "Acetaminophen/paracetamol"
            },
            {
              "name": "Diphenhydramine hydrochloride (HCl)"
            },
            {
              "name": "Methylprednisolone"
            },
            {
              "name": "Prednisone"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02191930",
          "briefTitle": "Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-03-16"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Cologne"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hodgkin Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "B-CAP"
            },
            {
              "name": "Brentuximab Vedotin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04090528",
          "briefTitle": "pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-10-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-11-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Wisconsin, Madison"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Castration-resistant Prostate Cancer",
            "Metastatic Cancer",
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "pTVG-HP"
            },
            {
              "name": "pTVG-AR"
            },
            {
              "name": "Pembrolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04839965",
          "briefTitle": "Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2021-07-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-02-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ampio Pharmaceuticals. Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID-19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ampion"
            },
            {
              "name": "Saline"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06134765",
          "briefTitle": "Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2023-11-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-10-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Second Affiliated Hospital, School of Medicine, Zhejiang University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Cancer",
            "Pancreatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 89,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bemalenograstim alfa"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06345365",
          "briefTitle": "MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-01-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Zhongnan Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Myeloid Leukaemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 154,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "mitoxantrone liposome, Ara-Cytarabine and azacitidine"
            },
            {
              "name": "Daunorubicin,Ara-Cytarabine, azacitidine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02048865",
          "briefTitle": "Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-03-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-10-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ottawa Hospital Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Venous Thromboembolism",
            "Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 575,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Apixaban"
            },
            {
              "name": "Placebo drug"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06692465",
          "briefTitle": "To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-04-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Suzhou Kintor Pharmaceutical Inc,"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Alopecia",
            "Male Pattern Hair Loss"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 180,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GT20029 Tincture"
            },
            {
              "name": "GT20029 matching placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00292071",
          "briefTitle": "Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merck Sharp & Dohme LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Fungal Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "caspofungin acetate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00000271",
          "briefTitle": "New Approaches to Cocaine Abuse Medications (A) - 6"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1995-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2002-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "New York State Psychiatric Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cocaine-Related Disorders",
            "Substance-Related Disorders"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 111,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Desipramine"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01468844",
          "briefTitle": "Minocycline to Treat Central Retinal Vein Occlusion"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-12-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-03-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Eye Institute (NEI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Retinal Vein Occlusion"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Minocycline"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Bevacizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03858634",
          "briefTitle": "A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-05-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-04-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Genentech, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Idiopathic Urticaria",
            "Chronic Idiopathic Pruritus",
            "Lichen Planus",
            "Lichen Simplex Chronicus",
            "Plaque Psoriasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "KPL-716"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04202809",
          "briefTitle": "Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC."
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-01-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital, Essen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "NSCLC, Stage III"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Durvalumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02650609",
          "briefTitle": "Treatment of Chronic Subdural Hematoma by Corticosteroids"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-06-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-03-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Rennes University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Subdural Hematomas"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 202,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Methylprednisolone"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06011109",
          "briefTitle": "Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-12-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Aveta Biomics, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Glioma",
            "Glioblastoma Multiforme"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "APG-157"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01437709",
          "briefTitle": "Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-09-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mantle Cell Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ofatumumab (This arm is closed)"
            },
            {
              "name": "Ofatumumab + Bendamustine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01514864",
          "briefTitle": "Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2012-05-31"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-07-23"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bristol-Myers Squibb"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Non-small Cell Lung"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dasatinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06605664",
          "briefTitle": "Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-05-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2029-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chang Gung Memorial Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma (HCC)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hyperpolarized 13C pyruvate MRI"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00605709",
          "briefTitle": "Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2008-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "BPGbio"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Squamous Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "API 31510 Topical Cream"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00973999",
          "briefTitle": "Botulinum Toxin and Saliva Management in Tracheotomised Patients"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2009-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "HCA International Limited"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Traumatic Brain Injury"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Botulinum Toxin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05060432",
          "briefTitle": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2021-09-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "iTeos Belgium SA"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Cancer",
            "Lung Cancer",
            "Head and Neck Cancer",
            "Melanoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 153,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "EOS-448"
            },
            {
              "name": "pembrolizumab"
            },
            {
              "name": "inupadenant"
            },
            {
              "name": "Dostarlimab"
            },
            {
              "name": "SOC chemotherapies"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02350998",
          "briefTitle": "Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Otonomy, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Bilateral Middle Ear Effusion"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "OTO-201"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00134498",
          "briefTitle": "A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hypertriglyceridemia",
            "Hyperlipoproteinemia Type IV"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 160
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "torcetrapib/atorvastatin"
            },
            {
              "name": "atorvastatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06166498",
          "briefTitle": "Parasite Clearance and Protection From Infection (PCPI) in Zambia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2024-07-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-19"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "London School of Hygiene and Tropical Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Malaria"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 600,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SP (Macleods Pharmaceuticals Ltd)"
            },
            {
              "name": "AS (Guilin Pharmaceuticals)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05998187",
          "briefTitle": "Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2023-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-06-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital, Rouen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Fecal Incontinence"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "intra-rectal botulinum toxin injections"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01695187",
          "briefTitle": "NB-001 Treatment of Recurrent Herpes Labialis"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2012-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "NanoBio Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Herpes Labialis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 362,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NB-001 (0.3%)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01907087",
          "briefTitle": "A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "BioMarin Pharmaceutical"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Jansky-Bielschowsky Disease",
            "Batten Disease",
            "Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2",
            "CLN2 Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BMN 190"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01915693",
          "briefTitle": "ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lisette Nixon"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Oesophageal Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 220,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Radiotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00067093",
          "briefTitle": "Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sanofi"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Deep Vein Thrombosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1452,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SanOrg34006"
            },
            {
              "name": "LMW heparin"
            },
            {
              "name": "Unfractionated heparin"
            },
            {
              "name": "Vitamin K antagonist (VKA)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00959114",
          "briefTitle": "Safety and Efficacy of ALV003 for the Treatment of Celiac Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alvine Pharmaceuticals Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Celiac Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 74,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ALV003"
            },
            {
              "name": "ALV003 placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02222714",
          "briefTitle": "Safety Evaluation of 3K3A-APC in Ischemic Stroke"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-04-18"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ZZ Biotech, LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ischemic Stroke"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 110,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "3K3A-APC"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05349214",
          "briefTitle": "Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2022-08-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-05-13"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sjogren Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 506,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "VAY736"
            },
            {
              "name": "VAY736"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01982916",
          "briefTitle": "Clinical Trial to Evaluate the Safety and Efficacy of AGR Tablet as a Treatment of Perennial Allergic Rhinitis in Korean"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ahn-Gook Pharmaceuticals Co.,Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Allergic Rhinitis",
            "Perennial Allergic Rhinitis",
            "Non-seasonal Allergic Rhinitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 324,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "AGR tablet"
            },
            {
              "name": "Placebo (for AGR tablet and/or Active Comparator)"
            },
            {
              "name": "Active Comparator"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04239716",
          "briefTitle": "Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-01-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-10-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tanta University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "regional anesthesia"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02112916",
          "briefTitle": "Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2014-10-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-03-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Adult T Acute Lymphoblastic Leukemia",
            "Ann Arbor Stage II Adult Lymphoblastic Lymphoma",
            "Ann Arbor Stage II Childhood Lymphoblastic Lymphoma",
            "Ann Arbor Stage III Adult Lymphoblastic Lymphoma",
            "Ann Arbor Stage III Childhood Lymphoblastic Lymphoma",
            "Ann Arbor Stage IV Adult Lymphoblastic Lymphoma",
            "Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma",
            "Childhood T Acute Lymphoblastic Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 847,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bortezomib"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Cytarabine"
            },
            {
              "name": "Daunorubicin"
            },
            {
              "name": "Daunorubicin Hydrochloride"
            },
            {
              "name": "Dexamethasone"
            },
            {
              "name": "Doxorubicin"
            },
            {
              "name": "Doxorubicin Hydrochloride"
            },
            {
              "name": "Etoposide"
            },
            {
              "name": "Hydrocortisone Sodium Succinate"
            },
            {
              "name": "Ifosfamide"
            },
            {
              "name": "Leucovorin Calcium"
            },
            {
              "name": "Mercaptopurine"
            },
            {
              "name": "Methotrexate"
            },
            {
              "name": "Pegaspargase"
            },
            {
              "name": "Radiation Therapy"
            },
            {
              "name": "Thioguanine"
            },
            {
              "name": "Vincristine"
            },
            {
              "name": "Vincristine Sulfate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05940506",
          "briefTitle": "Phase II Study Evaluating the Efficacy and Safety of KX-826"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-09-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-07-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Suzhou Kintor Pharmaceutical Inc,"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Androgenetic Alopecia (AGA)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "KX-826-2.5 mg (0.25%)/60 mL BID"
            },
            {
              "name": "KX-826-5 mg (5%)/60 mL QD"
            },
            {
              "name": "KX-826-5 mg (5%)/60 mL BID"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05766306",
          "briefTitle": "The Efficacy of a Probiotic Blend on Stress in Moderately Stressed Teens"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-03-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-02-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lallemand Health Solutions"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stress"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Probiotic Blend"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06954584",
          "briefTitle": "Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-05-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2030-05-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Tongji Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ovarian Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 424,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bevacizumab"
            },
            {
              "name": "Fluzoparib Monotherapy"
            },
            {
              "name": "Dietary Intervention"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00494884",
          "briefTitle": "Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes Mellitus, Type 2"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ]
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "vildagliptin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06687733",
          "briefTitle": "Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-07-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-07-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "NGGT (Suzhou) Biotechnology Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Phenylketonurias"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NGGT002"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05835804",
          "briefTitle": "Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centre Hospitalier Universitaire, Amiens"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Squamous Cell Carcinoma of the Head and Neck",
            "Paclitaxel",
            "Carboplatin",
            "Nivolumab"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 39,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GCP intratumoral catheter"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01024452",
          "briefTitle": "Randomized Comparison of Warfarin Dosing Quality Between the Hamilton Nomogram and a Commercial Computer System"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Population Health Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Patients at Risk for Thrombosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1298,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "DAWN AC"
            },
            {
              "name": "Hamilton Nomogram"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02110147",
          "briefTitle": "Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Wellstat Therapeutics"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hereditary Orotic Aciduria"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "uridine triacetate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01809847",
          "briefTitle": "Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Technische Universit\u00e4t Dresden"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Lymphatic Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ofatumumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04868149",
          "briefTitle": "Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-09-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The University of Hong Kong"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Liver Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07076849",
          "briefTitle": "Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-10-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2030-10-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Illinois at Chicago"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Iron Deficiency (ID)",
            "Pregnancy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lactiplantibacillus plantarum 299v"
            },
            {
              "name": "Placebo Capsule(s)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06285149",
          "briefTitle": "Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2024-03-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Henan Cancer Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HCC"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Icaritin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00589238",
          "briefTitle": "Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Centre, Singapore"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "carboplatin"
            },
            {
              "name": "cyclophosphamide"
            },
            {
              "name": "doxorubicin hydrochloride"
            },
            {
              "name": "paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03553758",
          "briefTitle": "EEG Studies of Ketamine General Anesthesia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-11-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-02-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Massachusetts General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anesthesia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ketamine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05563948",
          "briefTitle": "Repeated Administration of Cannabis Varying in THC and CBD"
        },
        "statusModule": {
          "overallStatus": "SUSPENDED",
          "startDateStruct": {
            "date": "2026-02-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2032-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "New York State Psychiatric Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cannabis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cannabis"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04291248",
          "briefTitle": "A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "MSI-H or dMMR Advanced Solid Tumors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 138,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "AK105"
            },
            {
              "name": "Anlotinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02073448",
          "briefTitle": "Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Galderma R&D"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acne Vulgaris"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 417,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GK530G"
            },
            {
              "name": "CD0271"
            },
            {
              "name": "CD1579"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01223248",
          "briefTitle": "Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2010-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melanoma",
            "Ovarian Cancer",
            "Sarcoma",
            "Bone",
            "CNS-Spinal CD/MEMBR, NOS",
            "Lymph Nodes",
            "Soft Tissue"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 220,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "IGIMRT using a single dose of 24 Gy"
            },
            {
              "name": "IGIMRT 27 Gy in 3 fractions"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03510455",
          "briefTitle": "BGJ398 for the Treatment of Tumor-Induced Osteomalacia"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2019-02-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-02-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Dental and Craniofacial Research (NIDCR)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Tumor-Induced Osteomalacia",
            "Oncogenic Osteomalacia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BGJ398"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02974855",
          "briefTitle": "PF-06741086 Multiple Dose Study in Severe Hemophilia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-03-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-12-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hemophilia A or B"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PF-06741086"
            },
            {
              "name": "PF-06741086"
            },
            {
              "name": "PF-06741086"
            },
            {
              "name": "PF-06741086"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00122278",
          "briefTitle": "Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Montefiore Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Migraine"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 205,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Dexamethasone"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06019507",
          "briefTitle": "A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2022-06-29"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "ITB-Med LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Liver Transplantation"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "TCD601"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "TAC"
            },
            {
              "name": "MMF"
            },
            {
              "name": "Corticosteroids"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05036707",
          "briefTitle": "Human Immune Response to Ixodes Scapularis Tick Bites"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-02-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Tick-borne Diseases",
            "Tick Resistance",
            "Lyme Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Xenodiagnosis Ticks"
            },
            {
              "name": "skin biopsy"
            },
            {
              "name": "blood draw"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03110107",
          "briefTitle": "First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2017-05-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-04-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bristol-Myers Squibb"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 376,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ipilimumab"
            },
            {
              "name": "BMS-986218"
            },
            {
              "name": "Nivolumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02807636",
          "briefTitle": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-06-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hoffmann-La Roche"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Urothelial Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1213,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Atezolizumab"
            },
            {
              "name": "Carboplatin"
            },
            {
              "name": "Gemcitabine"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Cisplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01236144",
          "briefTitle": "A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cardiff University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Myeloid Leukaemia",
            "High Risk Myelodysplastic Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 113,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Plerixafor"
            },
            {
              "name": "AC220"
            },
            {
              "name": "Ganetespib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02337634",
          "briefTitle": "Milk Thistle in Pathological Gambling"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Chicago"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pathological Gambling",
            "Gambling Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 55,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "Milk Thistle"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01777334",
          "briefTitle": "The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-01-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-09-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pulmonary Disease, Chronic Obstructive"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 905,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Umeclidinium/Vilanterol 62.5/25 mcg"
            },
            {
              "name": "Tiotropium 18 mcg"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00378664",
          "briefTitle": "Lumbar to Sacral Ventral Nerve Re-Routing"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Kenneth Peters, MD"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Urinary Incontinence",
            "Spinal Cord Injury",
            "Spina Bifida"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "lumbar to sacral ventral nerve re-routing procedure"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02576964",
          "briefTitle": "A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hoffmann-La Roche"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Hepatocellular"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Capecitabine"
            },
            {
              "name": "Peginterferon alfa-2a"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04533464",
          "briefTitle": "MultiStem\u00ae for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-11-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Healios K.K."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Trauma",
            "Adult Stem Cells"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 156,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "MultiStem"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01468064",
          "briefTitle": "Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Southern Medical University, China"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Stroke",
            "Infarction, Middle Cerebral Artery"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Autologous BMSCs transplantation"
            },
            {
              "name": "Autologous EPCs transplantation"
            },
            {
              "name": "IV infusion of placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04282109",
          "briefTitle": "Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-06-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Grupo Espa\u00f1ol de Tratamiento de Tumores de Cabeza y Cuello"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 141,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nivolumab + Paclitaxel"
            },
            {
              "name": "Cetuximab + Paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01470599",
          "briefTitle": "A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Crohn's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CP-690,550"
            },
            {
              "name": "CP-690,550"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01752699",
          "briefTitle": "Methadone in Post-Herpetic Neuralgia Pain"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1998-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Sao Paulo"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Post-herpetic Neuralgia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Methadone"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06738732",
          "briefTitle": "CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alexander Rotenberg"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lennox-Gastaut Syndrome (LGS)",
            "Dravet Syndrome (DS)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CBD: GT4 Transdermal Delivery System"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05130398",
          "briefTitle": "Safety and Immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambar\u00e9n\u00e9, Gabon"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-04-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-09-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centre de Recherche M\u00e9dicale de Lambar\u00e9n\u00e9"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ebola Virus Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "rVSV\u0394G-ZEBOV-GP, V920"
            },
            {
              "name": "Fibre and equilibrate breakfast and lunch"
            },
            {
              "name": "Active detection and treatment of pathogens"
            },
            {
              "name": "Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens"
            },
            {
              "name": "Chikenpox or Varicella vaccine (VARILRIX)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02383498",
          "briefTitle": "QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-05-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-09-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "NantCell, Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chordoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "GI-6301 Vaccine (Yeast- Brachyury)"
            },
            {
              "name": "Radiotherapy"
            },
            {
              "name": "wGT3X-BT Actigraph"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00389987",
          "briefTitle": "Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merck Sharp & Dohme LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Complicated Intra-Abdominal Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 300
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "MK0826, /Duration of Treatment : 8 Weeks"
            },
            {
              "name": "Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01447693",
          "briefTitle": "Treatment of Uremic Pruritus by Olive-omega 3 Ointment"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN"
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assaf-Harofeh Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Uremic Pruritus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "application of ointment (olive-omega 3 ointment)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00127621",
          "briefTitle": "Early Tracheotomy Versus Prolonged Endotracheal Intubation in Intensive Care Unit (ICU) Patients"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2002-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gustave Roussy, Cancer Campus, Grand Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Respiratory Insufficiency"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 468
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "early tracheotomy"
            },
            {
              "name": "prolonged endotracheal intubation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06183814",
          "briefTitle": "A Study of EXG102-031 in Participants With wAMD"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-10-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hangzhou Jiayin Biotech Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Neovascular Age-related Macular Degeneration"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "EXG102-031"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00000114",
          "briefTitle": "Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1984-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Eye Institute (NEI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Retinitis Pigmentosa"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ]
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Vitamin E"
            },
            {
              "name": "Vitamin A"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03270514",
          "briefTitle": "Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-11-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-13"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Kathirvel Subramaniam"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Coronary Artery Disease",
            "Coronary Artery Stenoses",
            "Valve Regurgitation, Mitral",
            "Valve Regurgitation, Tricuspid"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Exparel Injectable Product"
            },
            {
              "name": "Bupivacaine Hydrochloride"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00920816",
          "briefTitle": "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-08-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-07-27"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Neoplasms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 492,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Axitinib (AG-013736)"
            },
            {
              "name": "Sorafenib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04632316",
          "briefTitle": "A Trial to Evaluate the Safety and Efficacy of oNKord\u00ae in Subjects With Acute Myeloid Leukemia"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-12-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Glycostem Therapeutics BV"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Myeloid Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cyclophosphamide-Fludarabine (Cy/Flu)"
            },
            {
              "name": "oNKord\u00ae"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02620306",
          "briefTitle": "A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-02-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-23"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Boryung Pharmaceutical Co., Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Kidney Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 351,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fimsartan 60mg~120mg"
            },
            {
              "name": "Fimsartan 60mg~120mg"
            },
            {
              "name": "Losartan 50mg~100mg"
            },
            {
              "name": "Losartan 50mg~100mg"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02096406",
          "briefTitle": "Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Alberta"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Coronary Artery Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 126,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ACE/ARB continuation"
            },
            {
              "name": "ACE/ARB withdrawal"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01955252",
          "briefTitle": "Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lihir Medical Centre"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Yaws"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 16000,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Azithromycin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00260052",
          "briefTitle": "Erythropoietin Effects After Traumatic Brain Injury"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2003-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Medical College of Wisconsin"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Traumatic Brain Injury"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Erythropoietin administration"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03469804",
          "briefTitle": "Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-03-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assistance Publique - H\u00f4pitaux de Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kaposi Sarcoma",
            "Progression, Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 17,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pembrolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06142552",
          "briefTitle": "Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-12-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-01-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Jiangsu Gensciences lnc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Severe Hemophilia A"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "FRSW117"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04635852",
          "briefTitle": "Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Cologne"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cancer",
            "Dyspnea, Paroxysmal"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fentanyl"
            },
            {
              "name": "Immediate release morphine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01008852",
          "briefTitle": "Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Pfizer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Active Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "SBI-087"
            },
            {
              "name": "SBI-087"
            },
            {
              "name": "SBI-087"
            },
            {
              "name": "SBI-087"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05008484",
          "briefTitle": "Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-10-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06-13"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "VA Office of Research and Development"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Spinal Cord Injury"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NMES"
            },
            {
              "name": "Vitamin D"
            },
            {
              "name": "Passive movement"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00503152",
          "briefTitle": "Preventing Microalbuminuria in Type 2 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mario Negri Institute for Pharmacological Research"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diabetes"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 612,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Benazepril"
            },
            {
              "name": "Valsartan"
            },
            {
              "name": "Benazepril/Valsartan"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00666484",
          "briefTitle": "Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University College, London"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymphoma",
            "Neurotoxicity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "cyclophosphamide"
            },
            {
              "name": "doxorubicin hydrochloride"
            },
            {
              "name": "etoposide"
            },
            {
              "name": "prednisolone"
            },
            {
              "name": "procarbazine hydrochloride"
            },
            {
              "name": "vincristine sulfate"
            },
            {
              "name": "radiation therapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04115384",
          "briefTitle": "Intranasal Insulin in Frontotemporal Dementia (FTD)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2019-09-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-02-26"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "HealthPartners Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Frontotemporal Dementia, Behavioral Variant"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Novolin-R insulin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01008033",
          "briefTitle": "Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Dow Pharmaceutical Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Onychomycosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 870,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "IDP-108"
            },
            {
              "name": "Vehicle"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00554333",
          "briefTitle": "Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sanofi Pasteur, a Sanofi Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Influenza"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 795,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Flu-ID 15\u03bcg"
            },
            {
              "name": "Inactivated adjuvanted Influenza Vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03245333",
          "briefTitle": "A Study of Recombinant Human Growth Hormone Injection for Short Children With Small for Small for Gestational Age(SGA)"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2014-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Changchun GeneScience Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Small for Gestational Age Infant"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Recombinant Human Growth Hormone Injection"
            },
            {
              "name": "Recombinant Human Growth Hormone Injection"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07199504",
          "briefTitle": "A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2025-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Yunfeng Xia"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Restless Legs Syndrome in Patients With Uremia",
            "Dipyridamole"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "dipyridamole 50mg tid"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03616184",
          "briefTitle": "Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-09-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-01-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Nebraska"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Graft-versus-host-disease (GVHD)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 49,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ruxolitinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00575484",
          "briefTitle": "Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2007-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Barnes-Jewish Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Congestive Heart Failure",
            "Renal Insufficiency"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Hypertonic saline, then oral sodium chloride"
            },
            {
              "name": "Normal saline, then oral placebo capsule"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00867984",
          "briefTitle": "Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2009-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Calgary"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Heart Failure, Congestive"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Torsion optimized"
            },
            {
              "name": "Usual Care"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03299452",
          "briefTitle": "Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2017-01-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Haining Health-Coming Biotech Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Non Chemotherapy"
            },
            {
              "name": "Chemotherapy and target therapy"
            },
            {
              "name": "Chinese herb medicine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05647252",
          "briefTitle": "General Decolonization With Octenisan\u00ae Set Before Elective Orthopedic Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-02-27"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-11-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Balgrist University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Elective Surgery",
            "High Risk",
            "Prevention of Surgical Site Infections",
            "Randomized-controlled Trial"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1086,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Whole Body and nasal decolonization with octenidin (Octenisan Set)"
            },
            {
              "name": "Questionnaire for study participants immediately after the decolonization"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01392547",
          "briefTitle": "Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novo Nordisk A/S"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Congenital Bleeding Disorder",
            "Haemophilia A With Inhibitors",
            "Haemophilia B With Inhibitors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 72,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "vatreptacog alfa (activated)"
            },
            {
              "name": "eptacog alfa (activated)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00356447",
          "briefTitle": "Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bayer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Vasomotor Symptoms"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 249,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Estradiol/DRSP (Angeliq, BAY86-4891)"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00170547",
          "briefTitle": "Comparison of Delivery Routes of Flu Vaccine in Adults"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Influenza"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1597,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Trivalent inactivated influenza vaccine"
            },
            {
              "name": "Trivalent inactivated influenza vaccine"
            },
            {
              "name": "Trivalent inactivated influenza vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01244347",
          "briefTitle": "Folic Acid Dosage and Malformations Reduction"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2009-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Azienda Ospedaliera Universitaria Integrata Verona"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Congenital Malformations"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 5000,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "folic acid"
            },
            {
              "name": "folic acid"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00411138",
          "briefTitle": "Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2006-11-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-11-29"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Leiden University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Endometrial Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 670,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Radiation Therapy"
            },
            {
              "name": "cisplatin"
            },
            {
              "name": "carboplatin"
            },
            {
              "name": "Paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02244658",
          "briefTitle": "Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2014-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shandong University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Antineoplastic Adverse Reaction",
            "Thrombocytopenia",
            "Acute Myelocytic Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "rhTPO"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02138058",
          "briefTitle": "Topiramate Trial for Compulsive Buying"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2015-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Sao Paulo"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Compulsive Shopping"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Topiramate"
            },
            {
              "name": "Cognitive restructuring intervention"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01724658",
          "briefTitle": "Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chulalongkorn University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Female Sexual Dysfunction"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Testosterone undecanoate"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04150458",
          "briefTitle": "Fluorocholine PET/CT Basket Trial"
        },
        "statusModule": {
          "overallStatus": "ENROLLING_BY_INVITATION",
          "startDateStruct": {
            "date": "2022-11-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2030-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sir Mortimer B. Davis - Jewish General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Fluorocholine PET/CT"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 2000,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "18F-fluorocholine PET/CT."
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02011958",
          "briefTitle": "Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Drugs for Neglected Diseases"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Visceral Leishmaniasis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Liposomal Amphotericin B"
            },
            {
              "name": "Miltefosine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05848258",
          "briefTitle": "An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-05-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eli Lilly and Company"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rheumatoid Arthritis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 380,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "LY3871801"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03244358",
          "briefTitle": "Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2017-03-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Triple Negative Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Epalrestat"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07137858",
          "briefTitle": "Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-08-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Oral Squamous Cell Carcinoma (OSCC)",
            "Neoadjuvant Chemoimmunotherapy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Preoperative neoadjuvant immunotherapy chemotherapy"
            },
            {
              "name": "Two courses of preoperative neoadjuvant immunotherapy chemotherapy"
            },
            {
              "name": "Three courses of preoperative neoadjuvant immunotherapy chemotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04593758",
          "briefTitle": "To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613\u00ae (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-09-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-03-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cornerstone Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sarcoma, Clear Cell"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "CPI-613 + Hydroxychloroquine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00183248",
          "briefTitle": "Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Miami"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Transplantation",
            "Kidney Disease",
            "Kidney Failure"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Alemtuzumab"
            },
            {
              "name": "Mycophenolate mofetil"
            },
            {
              "name": "Sirolimus"
            },
            {
              "name": "Tacrolimus"
            },
            {
              "name": "Donor bone marrow stem cell infusion"
            },
            {
              "name": "Kidney transplant"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04030455",
          "briefTitle": "Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-08-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-11-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Laryngeal Squamous Cell Carcinoma",
            "Stage II Laryngeal Cancer AJCC v8",
            "Stage III Laryngeal Cancer AJCC v8"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Carboplatin"
            },
            {
              "name": "Cisplatin"
            },
            {
              "name": "Docetaxel"
            },
            {
              "name": "Pembrolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05935826",
          "briefTitle": "Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-06-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Colorado, Denver"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatic Steatosis",
            "NAFLD",
            "Adolescent Obesity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 55,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Essential Amino Acid Supplement by Amino Co"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05969626",
          "briefTitle": "Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2023-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ningbo Rongan Biological Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rabies"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 2460,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "5-dose group of test vaccine"
            },
            {
              "name": "5-dose group of control vaccine"
            },
            {
              "name": "4-dose A group of test vaccine"
            },
            {
              "name": "4-dose B group of test vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05583071",
          "briefTitle": "Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-08-23"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Cologne"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-Hodgkin Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tafasitamab"
            },
            {
              "name": "Lenalidomide"
            },
            {
              "name": "Rituximab"
            },
            {
              "name": "Methotrexate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00501371",
          "briefTitle": "MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2007-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Health Ever Bio-Tech Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Benign Prostatic Hyperplasia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 85,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "MCS"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03881371",
          "briefTitle": "A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-08-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Zambon SpA"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 307,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Safinamide"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00838071",
          "briefTitle": "Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2003-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2004-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Instituto Grifols, S.A."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatitis B, Chronic"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Specific intravenous anti-hepatitis B immunoglobulin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00283244",
          "briefTitle": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "UNC Lineberger Comprehensive Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 147,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "erlotinib hydrochloride"
            },
            {
              "name": "gemcitabine hydrochloride"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06957834",
          "briefTitle": "Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-06-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-07-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Skin Centre"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Melasma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Eflornithine hydrochloride cream"
            },
            {
              "name": "Hydroquinone cream"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00088309",
          "briefTitle": "Effect of Tenofovir DF on Bone Metabolism in Children"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Eye exam"
            },
            {
              "name": "Oral exam"
            },
            {
              "name": "CT scan"
            },
            {
              "name": "Neuropsychological testing"
            },
            {
              "name": "Electrocardiogram"
            },
            {
              "name": "Echocardiogram"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05448599",
          "briefTitle": "A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2022-07-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mabwell (Shanghai) Bioscience Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Myeloid Leukemia",
            "Myelodysplastic Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "6MW3211 injection with Intravenous Infusion"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00017199",
          "briefTitle": "PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ohio State University Comprehensive Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gastrointestinal Carcinoid Tumor",
            "Islet Cell Tumor"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ]
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "bortezomib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00158899",
          "briefTitle": "GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dyslipidaemias",
            "Dyslipidaemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 424,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GW501516 oral tablets"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05211232",
          "briefTitle": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2022-06-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-05-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nasopharyngeal Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 450,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tislelizumab"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02114632",
          "briefTitle": "Supplementation of Polyunsaturated Fatty Acids in Children With Attention Deficit/Hyperactivity Disorder (ADHD)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Medical University of Warsaw"
          }
        },
        "conditionsModule": {
          "conditions": [
            "ADHD"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 89,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Eye Q"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00844298",
          "briefTitle": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Asan Medical Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Leukemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 91,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nilotinib+mVPD"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02304198",
          "briefTitle": "Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Dong-A ST Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pulmonary Arterial Hypertension"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Udenafil"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03293498",
          "briefTitle": "Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2017-09-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-03-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novavax"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Influenza"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 330,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "NanoFlu"
            },
            {
              "name": "Fluzone HD - Day 0"
            },
            {
              "name": "Fluzone HD - Day 21"
            },
            {
              "name": "Saline - Day 21"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03977493",
          "briefTitle": "IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2018-02-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alain Kaelin"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Focal Hand Dystonia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Xeomin"
            },
            {
              "name": "Placebo - Concentrate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01866293",
          "briefTitle": "Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-05-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-08-18"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Memorial Sloan Kettering Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Relapsed or Refractory Multiple Myeloma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cabozantinib (XL184)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00120393",
          "briefTitle": "Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bristol-Myers Squibb"
          }
        },
        "conditionsModule": {
          "conditions": [
            "HIV Infections"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 192,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "atazanavir/ritonavir +2 NRTIs (immediate Switch Group)"
            },
            {
              "name": "LPV/r +2 NRTIs (Delayed/optional Switch Group)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04490421",
          "briefTitle": "Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer."
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-08-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Fuzhou General Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Neoplasm",
            "Small Cell Lung Cancer",
            "PD-1 Inhibitors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Camrelizumab combined with Apatinib, Etoposide and Cisplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01984021",
          "briefTitle": "Evaluation of the Immediate Effect of Acupuncture on the Upper Trapezius Muscle in Patients With Nonspecific Neck Pain."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Nove de Julho"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nonspecific Neck Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Acupuncture"
            },
            {
              "name": "Sham acupuncture"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01750814",
          "briefTitle": "To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2013-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Green Cross Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prophylaxis Against Influenza"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 400,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GC3102C"
            },
            {
              "name": "GC FLU inj."
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00316914",
          "briefTitle": "Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alliance for Clinical Trials in Oncology"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Cancer",
            "Neurotoxicity"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 104,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "calcium gluconate"
            },
            {
              "name": "magnesium sulfate"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07196306",
          "briefTitle": "Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2020-05-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2020-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "BayCare Health System"
          }
        },
        "conditionsModule": {
          "conditions": [
            "COVID",
            "COVID-19",
            "Corona Virus Infection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sarilumab 200 MG/1.14 ML Subcutaneous Solution"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06853704",
          "briefTitle": "The Clinical Effects of Using Collagen Matrix in Papilla Augmentation: a Prospective Clinical Trial. Augmenting Fibro-Gide in Interdental Area Using Tunneling Technique to Treat Black Triangles (Papilla Loss)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2023-06-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-07-20"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "King Abdullah University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dental Papilla Loss, Black Triangles",
            "Black Traingles",
            "Interdental Papillae Reconstruction",
            "Interdental Papilla Augmentation",
            "Interdental Papilla Loss"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "papillary unit advancement"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00269204",
          "briefTitle": "Lipid Efficacy/Tolerability Study (0524A-020)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Merck Sharp & Dohme LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Primary Hypercholesterolaemia",
            "Mixed Hyperlipidaemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1620,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "niacin (+) laropiprant"
            },
            {
              "name": "ER-niacin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02171104",
          "briefTitle": "MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2014-07-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-07-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Masonic Cancer Center, University of Minnesota"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Mucopolysaccharidosis Disorders",
            "Hurler Syndrome",
            "Hunter Syndrome",
            "Maroteaux Lamy Syndrome",
            "Sly Syndrome",
            "Alpha-Mannosidosis",
            "Fucosidosis",
            "Aspartylglucosaminuria",
            "Glycoprotein Metabolic Disorders",
            "Sphingolipidoses",
            "Recessive Leukodystrophies",
            "Globoid Cell Leukodystrophy",
            "Metachromatic Leukodystrophy",
            "Niemann-Pick B",
            "Niemann-Pick C Subtype 2",
            "Sphingomyelin Deficiency",
            "Peroxisomal Disorders",
            "Adrenoleukodystrophy With Cerebral Involvement",
            "Zellweger Syndrome",
            "Neonatal Adrenoleukodystrophy",
            "Infantile Refsum Disease",
            "Acyl-CoA Oxidase Deficiency",
            "D-Bifunctional Enzyme Deficiency",
            "Multifunctional Enzyme Deficiency",
            "Alpha-methylacyl-CoA Racmase Deficiency",
            "Mitochondrial Neurogastrointestingal Encephalopathy",
            "Severe Osteopetrosis",
            "Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation)",
            "Inherited Metabolic Disorders"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Stem Cell Transplantation"
            },
            {
              "name": "IMD Preparative Regimen"
            },
            {
              "name": "Osteopetrosis Only Preparative Regimen"
            },
            {
              "name": "Osteopetrosis Haploidentical Only Preparative Regimen"
            },
            {
              "name": "cALD SR-A (Standard-Risk, Regimen A)"
            },
            {
              "name": "cALD SR-B (Standard-Risk, Regimen B)"
            },
            {
              "name": "cALD HR-D (High-Risk, Regimen C)"
            },
            {
              "name": "cALD HR-D (High-Risk, Regimen D)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04246684",
          "briefTitle": "Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-11-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-09-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Prof. Dr. med. Claus R\u00f6del"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rectal Cancer Stage III"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 702,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Oxaliplatin, 85 mg/m2"
            },
            {
              "name": "5FU; 2400 mg/m2"
            },
            {
              "name": "5FU, 250 mg/m2"
            },
            {
              "name": "5FU, 2400 mg/m2"
            },
            {
              "name": "Oxaliplatin 50 mg/m2"
            },
            {
              "name": "Folinic Acid, 400 mg/m2"
            },
            {
              "name": "Radiotherapy control, 5x5 Gy: 25 Gy"
            },
            {
              "name": "Capecitabine, 1000 mg/m2"
            },
            {
              "name": "Oxaliplatin 85 mg/m2"
            },
            {
              "name": "radiotherapy experimental, 30 x 1,8 Gy: 54 Gy"
            },
            {
              "name": "Capecitabine, 825 mg/m2"
            },
            {
              "name": "Oxaliplatin, 130 mg/m2"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01569984",
          "briefTitle": "Radiosensitization of AVASTIN\u00ae (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Dr. Yoo-Joung Ko"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Cancer."
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Stereotactic body radiotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00579384",
          "briefTitle": "A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2008-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Photosensitive Epilepsy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "JNJ-26489112"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01899833",
          "briefTitle": "Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-05-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cell>Point LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Coronary Artery Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "99mTc-Sestamibi"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00395733",
          "briefTitle": "Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bayer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Vascular Diseases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 83,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gadobutrol (Gadavist, Gadovist, BAY86-4875)"
            },
            {
              "name": "Gadopentate dimeglumine (Magnevist, BAY86-4882)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00449033",
          "briefTitle": "A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2007-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bayer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 904,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Sorafenib (Nexavar, BAY43-9006)"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Gemcitabine"
            },
            {
              "name": "Cisplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02178852",
          "briefTitle": "TNS for Treating Nicotine Craving"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2014-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Santa Casa Medical School"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Nicotine Craving"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 22,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "TRIGEMINAL NERVE STIMULATION (TNS)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01357252",
          "briefTitle": "Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Type 2 Diabetes Mellitus"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 279,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "vildagliptin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03178747",
          "briefTitle": "Tzanck Smear With Methylene Blue Stain for Herpes"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2017-03-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-12-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Chulalongkorn University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Herpes Simplex",
            "Herpes Zoster",
            "Varicella Zoster"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Methylene blue"
            },
            {
              "name": "Giemsa stain"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02104947",
          "briefTitle": "Reversal of Dabigatran Anticoagulant Effect With Idarucizumab"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-05-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-07-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Boehringer Ingelheim"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hemorrhage"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 503,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "idarucizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02002247",
          "briefTitle": "SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX\u00ae-Trial)."
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2015-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Daren K. Heyland"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Heart Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1400,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "sodium selenite"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02485938",
          "briefTitle": "HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2016-01-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-09-14"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Capricor Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Duchenne Muscular Dystrophy",
            "Cardiomyopathy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Allogeneic Cardiosphere-Derived Cells (CAP-1002)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05502458",
          "briefTitle": "Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2020-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-08-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Zhejiang Cancer Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma",
            "Desflurane Adverse Reaction",
            "Propofol Adverse Reaction",
            "Circulating Tumor Cells"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Des\ufb02urane"
            },
            {
              "name": "Propofol"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01997255",
          "briefTitle": "Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2014-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Baylor College of Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Sturge Weber Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Everolimus"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00175955",
          "briefTitle": "Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2005-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "UCB Pharma"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Dyskinesia, Medication-induced"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Levetiracetam"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04538755",
          "briefTitle": "DAW2020 on OSA Endotypic Traits"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-11-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-05-15"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Brigham and Women's Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Obstructive Sleep Apnea (OSA)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo oral capsule"
            },
            {
              "name": "DAW2020 oral capsule"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03474926",
          "briefTitle": "Prognostic Value of Lymph Node Dissection in Patients With Transitional Cell Carcinoma of the Upper Urinary Tract"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2018-02-22"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-02-22"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "RenJi Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymph Node Dissection"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 504,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Routine Template-based lymphadenectomy"
            },
            {
              "name": "LND only for lymph nodes enlargement found in preoperative image or during surgery"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01450878",
          "briefTitle": "Renal Graft Function After Treatment With Erythropoietin (EPO)"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2011-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital, Limoges"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ischemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "beta-epoietin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02964078",
          "briefTitle": "Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2017-04-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-03-26"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H. Lee Moffitt Cancer Center and Research Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Pembrolizumab"
            },
            {
              "name": "Interleukin-2"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05645692",
          "briefTitle": "A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2023-04-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-12-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Hoffmann-La Roche"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Urothelial Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 204,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Atezolizumab"
            },
            {
              "name": "Tobemstomig"
            },
            {
              "name": "Tiragolumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06718192",
          "briefTitle": "A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts."
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-12-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The Fourth Affiliated Hospital of Zhejiang University School of Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Verruca Plantaris"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bleomycin injection"
            },
            {
              "name": "Cryotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01258192",
          "briefTitle": "Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage \u2161-\u2162 Esophageal Cancer Patients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Zhejiang Cancer Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Esophageal Squamous Cell Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "albumin-bound paclitaxel plus cisplatin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01278992",
          "briefTitle": "Rhodiola Rosea for Mental and Physical Fatigue"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2011-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Government of Alberta"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Fatigue"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Rhodiola rosea"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04444492",
          "briefTitle": "Combination of Ranibizumab and Targeted Laser Photocoagulation"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-08-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-11-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Giessen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Central Retinal Vein Occlusion With Macular Edema"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 110,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ranibizumab Injection"
            },
            {
              "name": "Laser photocoagulation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00063011",
          "briefTitle": "Bone Development in Adolescent Girls: Effects of Calcium and Exercise"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "1998-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Osteoporosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 107
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Calcium rich diet"
            },
            {
              "name": "Weight bearing exercise"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03919071",
          "briefTitle": "Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2020-02-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anaplastic Astrocytoma",
            "Anaplastic Astrocytoma, Not Otherwise Specified",
            "Anaplastic Ganglioglioma",
            "Anaplastic Pleomorphic Xanthoastrocytoma",
            "Glioblastoma",
            "Malignant Glioma",
            "WHO Grade 3 Glioma",
            "WHO Grade 4 Glioma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Biospecimen Collection"
            },
            {
              "name": "Dabrafenib Mesylate"
            },
            {
              "name": "Lumbar Puncture"
            },
            {
              "name": "Magnetic Resonance Imaging"
            },
            {
              "name": "Radiation Therapy"
            },
            {
              "name": "Trametinib Dimethyl Sulfoxide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00932971",
          "briefTitle": "HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "HepNet Study House, German Liverfoundation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatitis D"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "PEG-IFN alfa-2a, Tenofovir"
            },
            {
              "name": "PEG-IFN alfa-2a, placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02863471",
          "briefTitle": "Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2016-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University Hospital Tuebingen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Adenocarcinomas of the Pancreas"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 16,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gemcitabine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05545371",
          "briefTitle": "Prevention of Rabies With Four Doses of Rabies Vaccine"
        },
        "statusModule": {
          "overallStatus": "ENROLLING_BY_INVITATION",
          "startDateStruct": {
            "date": "2022-06-18"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-11-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Changchun Zhuoyi Biological Co., Ltd"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Rabies Human",
            "Antibody"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 2100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "immunization procedures"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04098744",
          "briefTitle": "Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2020-09-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-07-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Frantz Viral Therapeutics, LLC"
          }
        },
        "conditionsModule": {
          "conditions": [
            "CIN 2/3",
            "HPV Infection",
            "Pre-Cancerous Dysplasia",
            "Cervical Dysplasia",
            "HPV Related Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 78,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Artesunate vaginal insert"
            },
            {
              "name": "Placebo vaginal insert"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04818944",
          "briefTitle": "Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2023-03-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-01-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Iowa"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Acute Ischemic Stroke",
            "Ischemic Stroke"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tirofiban Hydrochloride"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00770744",
          "briefTitle": "Efficacy of Lu 31-130 in Patients With Schizophrenia"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "H. Lundbeck A/S"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Schizophrenia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 93,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Zicronapine"
            },
            {
              "name": "Olanzapine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06409364",
          "briefTitle": "FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2025-08-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2029-07-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "The George Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Aneurysmal Subarachnoid Hemorrhage"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 524,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Fludrocortisone"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00331409",
          "briefTitle": "Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "OHSU Knight Cancer Institute"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Kidney Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Everolimus"
            },
            {
              "name": "imatinib mesylate"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02134899",
          "briefTitle": "The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-10-14"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-11-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Assistance Publique - H\u00f4pitaux de Paris"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Autosomal Dominant Polycystic Kidney Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Everolimus"
            },
            {
              "name": "Calcineurin inhibitors maintenance"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01020799",
          "briefTitle": "AZD7268 Safety and Tolerability Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AstraZeneca"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Major Depressive Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 247,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "AZD7268"
            },
            {
              "name": "Escitalopram"
            },
            {
              "name": "Placebo capsules"
            },
            {
              "name": "Placebo tablets"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02409199",
          "briefTitle": "A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2015-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Shanghai Zhongshan Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Gastric Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Docetaxel"
            },
            {
              "name": "apatinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01933932",
          "briefTitle": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2013-09-25"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-06-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AstraZeneca"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 510,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Selumetinib"
            },
            {
              "name": "Docetaxel"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Pegylated G-CSF"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01306032",
          "briefTitle": "Phase II ABT-888 With Cyclophosphamide"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-01-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Ovarian Cancer",
            "Primary Peritoneal Cancer",
            "Serous Carcinoma Cancer",
            "Triple-Negative Breast Cancer",
            "Fallopian Tube Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 124,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "ABT-888"
            },
            {
              "name": "Cyclophosphamide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00005832",
          "briefTitle": "S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2000-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-10"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "SWOG Cancer Research Network"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 58,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "R115777"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03852498",
          "briefTitle": "A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2019-01-24"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-07-24"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Genetix Biotherapeutics Inc."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Cerebral Adrenoleukodystrophy (CALD)"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Lenti-D"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00924287",
          "briefTitle": "Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Fludarabine"
            },
            {
              "name": "Mesna"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02556593",
          "briefTitle": "IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2015-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non-Small Cell Lung Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "IMRT"
            },
            {
              "name": "WBRT"
            },
            {
              "name": "erlotinib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00975221",
          "briefTitle": "Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2010-03-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-07-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Amgen"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hyperparathyroidism, Primary",
            "Hypercalcemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cinacalcet"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05997693",
          "briefTitle": "One-Month DAPT in CABG Patients"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-08-15"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Weill Medical College of Cornell University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Coronary Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 700,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ticagrelor 90 MG"
            },
            {
              "name": "Low-dose aspirin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00362921",
          "briefTitle": "Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2004-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-08"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Duke University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Recurrent Adult Brain Tumor"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Gliadel wafers in combination with O6-benzylguanine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05962021",
          "briefTitle": "Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2023-08-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-06-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Peking University People's Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Non Squamous Non Small Cell Lung Cancer",
            "EGFR Positive Non-small Cell Lung Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 126,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Toripalimab plus Chemotherapy"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01608321",
          "briefTitle": "rTMS for the Treatment of Chronic Pain in GW1 Veterans"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2012-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-06"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "VA Office of Research and Development"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "rTMS"
            },
            {
              "name": "Sham device"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00005006",
          "briefTitle": "Parathyroid Hormone (PTH) With Alendronate for Osteoporosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1987-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2003-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Helen Hayes Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Osteoporosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 140,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Parathyroid Hormone"
            },
            {
              "name": "Alendronate"
            },
            {
              "name": "Teriparatide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07159906",
          "briefTitle": "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-09-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-08-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "First Affiliated Hospital of Zhejiang University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Diffuse Large B-Cell Lymphoma",
            "Relapsed Non-Hodgkin Lymphoma",
            "Refractory Non-Hodgkin Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 62,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Homoharringtonine"
            },
            {
              "name": "BCL-2 inhibitor"
            },
            {
              "name": "CD20 Antibody"
            },
            {
              "name": "Glucocorticoid (GC)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02247206",
          "briefTitle": "VoIP Delivered Behavior Therapy for Tourette Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2012-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Wisconsin, Milwaukee"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Tourette Syndrome",
            "Chronic Tic Disorder"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Behavior Therapy for Tics (CBIT)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03989206",
          "briefTitle": "Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-12-30"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-08-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Galderma R&D"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Moderate-to-Severe Atopic Dermatitis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1700,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Nemolizumab"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02173704",
          "briefTitle": "Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-09-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2015-12-25"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "GlaxoSmithKline"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Meningococcal Disease",
            "Infections, Meningococcal"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 225,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bexsero\u00ae"
            },
            {
              "name": "Routine vaccines"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02864004",
          "briefTitle": "Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2017-03-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Rennes University Hospital"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Parkinson's Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 134,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Apomorphine"
            },
            {
              "name": "Best Medical Treatment"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01428804",
          "briefTitle": "Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-07"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centre Hospitalier Universitaire de Besancon"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Resistant Major Depression"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "transcranial Direct Current Stimulation (tDCS)"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00003084",
          "briefTitle": "Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "1997-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2002-11"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 75,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Doxorubicin Hydrochloride"
            },
            {
              "name": "Estramustine phosphate sodium"
            },
            {
              "name": "Etoposide"
            },
            {
              "name": "Ketoconazole"
            },
            {
              "name": "Paclitaxel"
            },
            {
              "name": "Vinblastine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05310084",
          "briefTitle": "Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2022-04-20"
          },
          "primaryCompletionDateStruct": {
            "date": "2022-10-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "BioNTech SE"
          }
        },
        "conditionsModule": {
          "conditions": [
            "SARS-CoV-2 Infection",
            "COVID-19"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1134,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BNT162b2"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Seasonal Inactivated Influenza Vaccine"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01772433",
          "briefTitle": "Olive Oil Phonophoresis and Chronic Low Back"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2013-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-09"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ardabil University of Medical Sciences"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Low Back Pain"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Olive oil"
            },
            {
              "name": "Phonophoresis gel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05926206",
          "briefTitle": "Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas"
        },
        "statusModule": {
          "overallStatus": "WITHDRAWN",
          "startDateStruct": {
            "date": "2023-07"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Michigan Rogel Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Pancreatic Adenocarcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Devimistat"
            },
            {
              "name": "Modified FOLFIRINOX"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05240404",
          "briefTitle": "Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma"
        },
        "statusModule": {
          "overallStatus": "UNKNOWN",
          "startDateStruct": {
            "date": "2020-07-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-07-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Xiangya Hospital of Central South University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatocellular Carcinoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 116,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Toripalimab"
            },
            {
              "name": "Thermal ablation"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03878004",
          "briefTitle": "Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Healthy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 180,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "GamTBvac vaccine"
            },
            {
              "name": "placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01571804",
          "briefTitle": "Pregabalin Reduce the Sevoflurane Requirement"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2011-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-02"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mansoura University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Elective Laparoscopic Cholecystectomy",
            "Sevoflurane Anesthesia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Placebo"
            },
            {
              "name": "pregabalin"
            },
            {
              "name": "pregabalin"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06662604",
          "briefTitle": "Using of Bone Marrow Stem Cell Concentrate with Platelet Rich Fibrin and Bone Graft in Bone Reconstruction of Upper Jaw Bony Cystic Defects, Comparing with Platelet Rich Fibrin with Bone Graft"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2024-10-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-09-17"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Cairo University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Maxillary Cyst"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 22,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Bone marrow stem cells concentrate , platelet rich fibrin , bone graft"
            },
            {
              "name": "platelet rich fibrin and bone graft"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06031584",
          "briefTitle": "A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2024-01-19"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sichuan Baili Pharmaceutical Co., Ltd."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Her2-positive/Low-expression Urinary and Digestive Tract Tumors"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "BL-M07D1"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05463484",
          "briefTitle": "Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral Dysbiosis"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2021-07-13"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-02-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Mucosa Innovations, S.L."
          }
        },
        "conditionsModule": {
          "conditions": [
            "Oral Dysbiosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Test composition Saliactive\u00ae (olive product, betaine and xylitol)"
            },
            {
              "name": "Placebo"
            },
            {
              "name": "Control"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00362752",
          "briefTitle": "A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2006-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Unity Health Toronto"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Hepatopulmonary Syndrome"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Norfloxacin"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01977547",
          "briefTitle": "Age of Blood in Children in Pediatric Intensive Care Units"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-12"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Washington University School of Medicine"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Anemia"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 1538,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Short storage RBC age"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00600249",
          "briefTitle": "Assessment of the Efficacy of a Neoadjuvant Combination: \"Chemotherapy-targeted Therapy\" in Breast Cancer."
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-05"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Centre Jean Perrin"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Cetuximab"
            },
            {
              "name": "Docetaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03724149",
          "briefTitle": "Transplanting Hepatitis C Lungs Into Negative Lung Recipients"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2018-12-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2021-12-31"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "University of Pennsylvania"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lung Diseases"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Zepatier"
            },
            {
              "name": "Epclusa"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04920149",
          "briefTitle": "Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2022-03-21"
          },
          "primaryCompletionDateStruct": {
            "date": "2032-09-30"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Ann-Sofie Backman"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lynch Syndrome",
            "Colon Cancer",
            "Colon Neoplasm"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Mesalamine"
            },
            {
              "name": "Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01799538",
          "briefTitle": "Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2013-06-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-11-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "National Heart, Lung, and Blood Institute (NHLBI)"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Lymphangioleiomyomatosis"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "albuterol inhaler"
            },
            {
              "name": "albuterol nebulizer"
            },
            {
              "name": "PFT"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05941338",
          "briefTitle": "Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2023-03-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-02-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Head and Neck Squamous Cell Carcinoma",
            "Oral Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Tirelizumab ,+Carboplatin+albumin-bound paclitaxel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00033748",
          "briefTitle": "Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2001-12"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-03"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Alliance for Clinical Trials in Oncology"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Colorectal Cancer",
            "Metastatic Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 56,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "monoclonal antibody 11D10 anti-idiotype"
            },
            {
              "name": "monoclonal antibody 3H1 Alu Gel"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05201248",
          "briefTitle": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2022-03-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Genmab"
          }
        },
        "conditionsModule": {
          "conditions": [
            "B-Cell Non-Hodgkin Lymphoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 49,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Epcoritamab"
            },
            {
              "name": "Cyclophosphamide"
            },
            {
              "name": "Rituximab"
            },
            {
              "name": "Doxorubicin"
            },
            {
              "name": "Vincristine"
            },
            {
              "name": "Prednisone"
            },
            {
              "name": "Lenalidomide"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT07049848",
          "briefTitle": "SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma"
        },
        "statusModule": {
          "overallStatus": "NOT_YET_RECRUITING",
          "startDateStruct": {
            "date": "2025-12-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2028-01-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Soft Tissue Sarcoma"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Atezolizumab"
            },
            {
              "name": "Doxorubicin Hydrochloride"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04007055",
          "briefTitle": "The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2019-08-09"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-03-28"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Marissa Jarosinski"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Peripheral Artery Disease",
            "Clopidogrel, Poor Metabolism of",
            "Peripheral Vascular Disease",
            "Artery Disease",
            "Peripheral Arterial Occlusive Disease"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Point of care screening for HPR"
            },
            {
              "name": "Ticagrelor 90mg"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00863655",
          "briefTitle": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-06-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-12-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis Pharmaceuticals"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 724,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Everolimus"
            },
            {
              "name": "Exemestane"
            },
            {
              "name": "Everolimus Placebo"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03131726",
          "briefTitle": "Treatment of Graves\u00b4ophthalmopathy with Simvastatin (GO-S)"
        },
        "statusModule": {
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2018-01-26"
          },
          "primaryCompletionDateStruct": {
            "date": "2027-01-26"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Lund University"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Graves Ophthalmopathy",
            "Thyroid Associated Ophthalmopathy",
            "Thyroid Associated Orbitopathy"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE3"
          ],
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Simvastatin 40mg"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00785226",
          "briefTitle": "RDEA119 and Sorafenib Combination Dose Escalation Study"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2008-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-04"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Bayer"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 62,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "RDEA119"
            },
            {
              "name": "Sorafenib"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03831178",
          "briefTitle": "Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting"
        },
        "statusModule": {
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "startDateStruct": {
            "date": "2019-08-28"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-12-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "AHS Cancer Control Alberta"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 76,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Docosahexaenoic acid (DHA)"
            },
            {
              "name": "Placebo oral capsule"
            }
          ]
        }
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00638378",
          "briefTitle": "Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer"
        },
        "statusModule": {
          "overallStatus": "TERMINATED",
          "startDateStruct": {
            "date": "2008-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-01"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Incyte Corporation"
          }
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ]
        },
        "designModule": {
          "phases": [
            "PHASE2"
          ],
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "name": "Ruxolitinib"
            }
          ]
        }
      }
    }
  ]
}